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The elderly population is growing in nursing homes (NHs), with an estimated 3 million 
seniors to be residing in NH facilities by year 2030. Many of these seniors are potentially at risk 
for falls or infections. NH residents with Alzheimer’s disease or other forms of dementia are also 
increasing, and they are vulnerable to the adverse effects of medications.   
Psychotropics are overused in NHs, with approximately half to two thirds of residents 
receiving one or more psychotropics. Many negative health outcomes, e.g. falls and infections, 
have been associated with their use. The usage of psychotropic medications among NH residents 
has been a concern and topic of scrutiny for nearly three decades. In 1986, the Institute of 
Medicine published a landmark report that identified the overuse of psychotropic medications in 
NHs. The following year, the federal government passed the Omnibus Budget Reconciliation Act 
that included reform legislation to address psychotropic drug overuse. 
Since then, additional policies and initiatives have endeavored to rectify the problem, and 
scientists have conducted research regarding psychotropics and negative health outcomes. 
However, newer research within the last decade and at a national level is lacking. Therefore, this 
dissertation explores the association of psychotropic medications with falls and infections among 
NH residents using a national dataset, and this document is organized into five chapters. The first 
chapter discusses the background, significance, and current challenges surrounding psychotropic 
medication use in NHs. The second chapter delineates the search of the literature and relevant 
findings. The third chapter describes the methodology upon which this analytics of this 
 
 
dissertation was conducted. The fourth chapter outlines the results from the analyses. Lastly, the 
fifth chapter provides a synthesis and discussion of the findings and recommendations for health 
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Chapter 1 – Introduction 
This dissertation focused on psychotropic medication administration to nursing 
home (NH) residents within the context of resident safety across the United States (U.S.). 
This chapter is organized in the following manner. First, a description of NHs and the 
population they serve is provided. Second, an overview of psychotropic medications, 
their administration to NH residents and its importance in resident safety is provided. The 
focus of resident safety was on two important preventable adverse events: falls and 
infections. The rationale for concentrating on these two events is discussed. Third, the 
data used for this dissertation were from the Minimum Data Set (MDS), the Online 
Survey Certification and Reporting (OSCAR) system, and the Certification and Survey 
Provider Enhanced Reporting (CASPER) system. An overview of the data sets is 
provided. Fourth, the theoretical framework guiding this dissertation is presented. It is an 
adaptation of Donabedian’s health care quality framework, which identifies three stages 
of care delivery – structure, process, and outcome. Donabedian developed this theory to 
assess the quality of health care delivery, and the adapted framework includes resident 
characteristics, which influence each stage. Next, the significance of this dissertation and 
the gaps that it intends to address are discussed. Finally in the conclusion of this chapter, 






Description of Nursing Homes and the Nursing Home Population 
A NH is a long-term care facility that provides its residents with a broad range of 
services such as support for personal care needs, social activities, and medical care 
(Gertler, 1989; Medicare.gov). Some of the services provided in NHs are focused on 
lifestyle maintenance, and others are towards rehabilitation and transitional support for 
return into the community (Gertler, 1989; U.S. Department of Health & Human Services, 
2013). According to a report based on the 2004 National Nursing Home Survey, 
approximately 88% of NH residents were elderly age 65 and older (Jones, Dwyer, 
Bercovitz, & Strahan, 2009). 
NHs provide housing for residents needing a range of care from minimal support 
for personal care to 24-hour skilled nursing care. Assistance for everyday personal care 
tasks, commonly referred to as activities of daily living (ADLs), include help with 
bathing, dressing, eating, getting in or out of bed, and moving about (Medicare.gov; U.S. 
Department of Health & Human Services, 2013). ADLs are an integral part of assessing 
functional status for NH residents (Mystakidou et al., 2013). 
The NH population is increasing, and more NH residents are potentially at risk for 
falls or infections. The U.S. population of seniors age 65 and older is projected to 
increase from 40.2 million in 2010 to 88.5 million in 2050 (Vincent & Velkoff, 2010). A 
large part of this increase is a result of the influx starting in 2011 of baby boomers, those 





estimated that more than 67% of Americans age 65 and older will require long-term care 
services, and as of December 2012 over 1.4 million people were residing in NHs (Centers 
for Medicare & Medicaid Services, 2013; Harris-Kojetin, Sengupta, Park-Lee, & 
Valverde, 2013). It is estimated that by 2030, the number of seniors age 65 and older 
residing in NHs could reach approximately 3 million (Centers for Disease Control and 
Prevention; Sahyoun, Pratt, Lentzner, Dey, & Robinson, 2001). 
The number of seniors diagnosed with Alzheimer’s disease and other forms of 
dementia is increasing, and this population, many of whom will be residents in NHs, are 
vulnerable to the adverse effects of medications. For seniors aged 65 and older, it is 
estimated that 13 million (or 15% of this age group) will be diagnosed with a form of 
dementia by the year 2050 (Alzheimer's Association, 2014; Goldfeld, Stevenson, Hamel, 
& Mitchell, 2011). Individuals diagnosed with Alzheimer’s disease or other forms of 
dementia are almost nine times more likely to require NH care than individuals without 
such diagnoses (Clark et al., 2013). In 2001, approximately 70% of the deaths for seniors 
age 65 and older with dementia occurred in NHs (Mitchell, Teno, Miller, & Mor, 2005).  
 
Psychotropic Medications are Over Used in Nursing Home Residents 
Psychotropic medications often used in NHs include antipsychotics, 
antidepressants, antianxiety, and hypnotics, and these medications are prescribed to 





delusion (Brandt & Pythtila, 2013; Galik & Resnick, 2013; Schneider, Dagerman, & 
Insel, 2005). Antipsychotics are categorized into two classes, typical/conventional (first 
generation) and atypical (second generation) (Wang et al., 2005); and, according to the 
Food and Drug Administration (FDA) approval guidelines, atypical antipsychotics are 
indicated primarily for patients with schizophrenia or bipolar disorder but can also be 
used for “off-label” purposes, such as treating patients with dementia and behavioral 
symptoms (Bowblis, Crystal, Intrator, & Lucas, 2012; Gellad et al., 2012). Atypical 
antipsychotics are often preferred because they less frequently cause extrapyramidal 
symptoms, e.g. continuous muscle contractions, rigidity, and irregular, jerky movements 
(Gareri, De Fazio, Stilo, Ferreri, & De Sarro, 2003).  
Researchers have found that approximately half to two thirds of NH residents 
receive one or more psychotropic medications (Bhattacharjee, Karkare, Kamble, & 
Aparasu, 2010; Eggermont, de Vries, & Scherder, 2009; Galik & Resnick, 2013; Kim & 
Whall, 2006). In one study, investigators reported that certain psychotropic drugs can 
often be used for short durations to treat agitation, and thus they are frequently prescribed 
around NH admission (Rochon et al., 2008).  An overview of psychotropic drug 









Table 1  Overview of Psychotropic Drugs 
 
  
Classification Subtype Classes Indications Drug Examples^









Antidepressant Selective Serotonin Reuptake Inhibitors (SSRIs)
Serotonin-Norepinephrine Reuptaek Inhibitors (SNRIs)
Tricyclic Antidepressant (TCAs)
Monoamine Oxidase Inhibitors (MAOIs)
Reversible Monoamine Oxidase A Inhibitors (rMAO-A Inhibitors)
Tetracyclic Antidepressants (TeCAs)




































Almost 3 decades ago, a report by the Institute of Medicine (IOM) identified 
psychotropic medication overuse in NHs (Institute of Medicine, 1986). As a result, the 
Omnibus Budget Reconciliation Act (OBRA) that was passed the following year 
included federal NH reform legislation that addressed the overuse of psychotropic 
medications. The new policies set guidelines for appropriate psychotropic medication 
usage and sanctions for NHs that used them unnecessarily (Bowblis et al., 2012; Garrard, 
Chen, & Dowd, 1995).  
More recently in April 2005, the FDA issued a black box warning that atypical 
antipsychotic medications were associated with increased mortality for persons with 
dementia (Bowblis et al., 2012; Galik & Resnick, 2013; Gellad et al., 2012). A black box 
warning is the highest of five warning category levels for drug package inserts and is 
designed to bring attention to risks that are serious or life-threatening (Aaronson, 2006; 
Food and Drug Administration, 2012). Later in 2008, the FDA also applied this black box 
warning to conventional/typical antipsychotic medications (Bowblis et al., 2012; Galik & 
Resnick, 2013). 
Despite the report, legislation, and warnings, NH residents may still be 
inappropriately prescribed psychotropic medications. In a 2010 research study of a 
national sample of newly admitted NH residents, inconsistent and overuse of 
psychotropic medications were still found to occur, and 32% of those given such 
medications were done so without any identified indication for use (Chen et al., 2010). In 
a report issued by the Office of Inspector General in the Department of Health and 





antipsychotic drugs were not administered in compliance with guidelines as set by the 
Centers for Medicare and Medicaid Services (CMS) (Bowblis et al., 2012; Gellad et al., 
2012; Levinson, 2011). Examples of facility non-compliance included antipsychotic 
drugs being used in excessive dose, in excessive duration, without adequate indication(s) 
for use, or without adequate monitoring (Levinson, 2011). 
In 1991, a panel of experts developed the Beers’ Criteria for evaluating the use of 
potentially inappropriate medications among NH residents, and many psychotropic 
medications are included in that reference (Beers, 1997). The Beers’ Criteria were 
updated in 1997 and 2003, and it has become the gold standard for appraising the 
prescription of potentially inappropriate medications to elders, whether in the NH or in 
the community (Barry, O'Keefe, O'Connor, & O'Mahony, 2006). The most recent update 
of the Beers’ Criteria contains: 1) the 48 classes of medications or individual medications 
to avoid for the elderly, 2) the 20 conditions or diseases and medications that should be 
avoided for elderly with those conditions, and 3) the list of changes from the previous 
edition (Fick et al., 2003).  
The Beers’ Criteria were not meant to be a substitute for careful decision making 
by physicians and pharmacists. Rather it was a tool for aiding in identifying potentially 
inappropriate medications for the elderly (Beers, 1997). Despite the prescription 
guidelines provided by the Beers’ Criteria, potentially inappropriate psychotropic 
medications are still prescribed to NH residents (Agashivala & Wu, 2009). The MDS 
data does not identify individual medications that are administered to NH residents, and 





Negative Resident Outcomes are Associated with Psychotropic Medication Usage 
The use of psychotropic drugs in NHs has been associated with numerous 
negative outcomes, including physical disability, pneumonia and other infections, 
depressed mood, sedation, and increased risk for falls (Echt, Samelson, Hannan, Dufour, 
& Berry, 2013; Galik & Resnick, 2013; C. Huang et al., 2014; Rogers et al., 2013). 
Physical health outcomes, such as physical function, gait, and balance, were significantly 
lower in those NH residents receiving psychotropic medications (Galik & Resnick, 
2013).  
Falls and Infections are Serious Concerns in Nursing Home Residents and may be 
Associated with Psychotropic Medication Usage 
Falls are a serious concern in NHs nationwide. In the U.S., more than 33% of 
seniors age 65 and older have a fall each year (Stevens, Corso, Finkelstein, & Miller, 
2006). Within the NH setting, approximately 75% of the residents will fall each year, and 
about 10% of those will receive a serious injury, such as a fracture or head trauma (Echt 
et al., 2013; Stevens et al., 2006). Approximately 1,800 seniors living in NHs die 
annually from a fall-associated injury (Centers for Disease Control and Prevention; 
Rubenstein, Josephson, & Robbins, 1994).  
The number of falls can rise with age, and the accompanying injuries and 
complications are associated with poor prognoses, such as excess mortality (Hartikainen, 
Lonnroos, & Louhivuori, 2007). Approximately 10% to 20% of falls in NHs cause 
serious injury, with some resulting in permanent disability, functional decline, and 





and older, falls are the primary reason for injuries (Findorff, Wyman, Nyman, & 
Croghan, 2007). As such, falls and their related injuries are very important health 
concerns for vulnerable NH residents (Echt et al., 2013; Stevens et al., 2006). In the U.S., 
upwards of an estimated $20 billion dollars is spent annually to cover the medical costs 
due to falls for seniors age 65 and older (Stevens et al., 2006).  
Psychotropic medication use in NH residents can considerably increase the risk of 
falls from 30 to 70% (Echt et al., 2013; Hartikainen et al., 2007; Lustenberger, 
Schupbach, von Gunten, & Mosimann, 2011). Impaired gait and balance, found to be 
present in NH residents administered psychotropic medications, may potentially present 
as a significant fall risk for the NH residents (Galik & Resnick, 2013).  
Another very important health concern for NH residents is infection. Health care-
associated infections in the U.S. are a leading cause of death annually and are a national 
priority (U.S. Department of Health & Human Services, 2013). In 2008, subject matter 
experts convened to address the elimination of infections associated with health care 
facilities and create a National Action Plan; and, the experts represented multiple national 
agencies, including CMS, HHS, Agency for Healthcare Research and Quality, 
Administration on Aging, Administration for Community Living, and many others (U.S. 
Department of Health & Human Services, 2013). In 2013, Phase 3 of the Action Plan was 
extended to include infection prevention in long-term care facilities.  
Incidences of infection are high among NH residents and are a common cause for 
increased morbidity and mortality (Nicolle, 2000; Richards, 2007). Infection rates in U.S. 





Infections in NHs are contributors to direct and indirect health care costs, with the cost of 
antibiotics alone being estimated at $38-137 million per year (Dwyer et al., 2013; 
Strausbaugh & Joseph, 2000). Annually, infections in NHs could account for more than 
150,000 transfers to hospitals, and those hospitalizations result in an additional $673 
million in health care costs (U.S. Department of Health & Human Services, 2013).  
 Researchers have found that the use of certain psychotropic drugs are associated 
with an increased risk for infections (C. Huang et al., 2014; Rogers et al., 2013). 
Investigators discovered that the use of a certain sedative/hypnotic and antipsychotic 
medications were linked to several types of infection, such as pneumonia, bronchitis, and 
septicemia (C. Huang et al., 2014; Knol et al., 2008). In another study, researchers found 
that the use of various antidepressant medications were associated with the risk of 
Clostridium difficile infection (Rogers et al., 2013). 
 
Using the MDS, OSCAR, & CASPER to Measure Drug Usage and 
Outcomes 
In response to a mandate from the OBRA of 1987, the standardized Resident 
Assessment Instrument (RAI) was developed in 1990 for use in NHs nationwide (Hawes 
et al., 1995; Morris et al., 1994). The MDS is the care component of the RAI to assess 
NH resident condition (Hartmaier et al., 1995; Langmore, Skarupski, Park, & Fries, 2002; 
Morris et al., 1994). The MDS is employed in all U.S. NHs that are certified by CMS, 
and it is an excellent source of data (Kohler & Wunderlich, 2001; Shin & Scherer, 2009). 





members of the NH facility (Hartmaier et al., 1995; Morris et al., 1994). Comprehensive 
MDS assessments are conducted upon admission, annually, or if there is any significant 
change in the NH resident’s condition, and a condensed MDS version is conducted 
quarterly (Carpenter, Hastie, Morris, Fries, & Ankri, 2006; Hartmaier et al., 1995; Hawes 
et al., 1995; Langmore et al., 2002; Morris et al., 1994). 
The MDS is a national, uniform assessment that is regulated by the CMS and 
open to CMS audit. Incorrect or inaccurate reports are subject to penalties, and MDS 
assessments are tied to CMS reimbursement. After the initial development, a second 
version of the MDS (2.0) was introduced in 1995, and a third version (3.0) was 
implemented in 2010. The federal government, through its iterations of MDS, aims to 
collect data to describe the NH resident population, to generate quality indicators for 
guiding improvements, and to gather data for CMS reimbursement (Rahman & 
Applebaum, 2009). The MDS items include important clinical information of each 
resident, such as disease diagnoses (including infections), health conditions, cognitive 
functioning, medications (including psychotropics), falls, ADLs, and psychological 
functioning among many others (Hawes et al., 1995; Huybrechts et al., 2012). 
OSCAR is an administrative data network maintained by CMS, and it provides 
data for all certified NHs. This certification is required for facilities to participate in the 
Medicare and Medicaid programs (Daly, Bay, Levy, & Carnahan, 2015; Newman & 
Cauley, 2012). OSCAR provides comprehensive facility level information such as facility 
characteristics, staffing levels, summarized health status of residents, and facility 





this survey data is entered into the OSCAR system (Agency for Healthcare Research and 
Quality, 2000; Newman & Cauley, 2012). In 2012, the OSCAR system was renamed the 
CASPER system, but the same facility level data that were available in OSCAR are 
available in CASPER for facilities certified by CMS (Daly et al., 2015).  
This dissertation will include the years 2011 and 2013, and therefore the data will 
be extracted from MDS 3.0 and OSCAR/CASPER data sets. The MDS has been shown 
in studies to be a reliable instrument in both clinical and research applications (Hawes et 
al., 1995; Huybrechts et al., 2012; Morris et al., 1990). Also, OSCAR data for clinical 
measures was shown by researchers to be generally reliable and consistent and was 
comparable to the same clinical measures as in the MDS (N. J. Zhang, Paek, & Wan, 
2009). Therefore, the MDS and OSCAR/CAPSER data sets are appropriate for use in this 
dissertation. 
 
Donabedian’s Health Care Quality Framework 
The dissertation will be guided by an adapted framework based on Donabedian’s 
health care quality framework, which was developed to assess the quality of health care 
delivery (Donabedian, 1966, 1988). According to this model, the features of the health 
care delivery system are grouped into three parts: structure, process, and outcome 
(Donabedian, 1966, 1988; McDonald KM, 2007). According to Donabedian, the 
structures of care include administrative and related processes that support and direct the 
provision of care, the processes of care include the delivery of care services and the 





consequential results of the care delivery as framed by the structures and processes 
(Donabedian, 1966). Based on Donabedian’s framework, I constructed a model of the 
adapted theoretical framework (shown in Figure 1). 
 
Figure 1  Adapted Framework of Health Care Quality 
 
This conceptual framework is relevant for this study because it aims to examine 
associations between the facility processes (i.e., use of psychotropic medications) and NH 
resident health outcomes. The resident characteristics have a relationship with each of the 
three dimensions of health care quality, as shown in the above model. The structures of 
care are the facility characteristics (e.g. bed size, location, staffing). The processes for 
this study are the administration of psychotropic medication to NH residents. The 





status, and dementia diagnosis. The outcomes of interest for this study are falls and 
infections in NH residents.  
 
Definition of Falls 
The definition of a fall is not universally consistent amongst seniors and health 
care facilities, and as such, many falls may go unreported (Centers for Disease Control 
and Prevention; A. R. Huang et al., 2012). According to the World Health Organization 
(WHO), a fall is defined as “an event which results in a person coming to rest 
inadvertently on the ground or floor or other lower level” (World Health Organization, 
2012). Some researchers have investigated the consequences of falls, such fractures or 
hospitalizations, but this proposal will focus on falls in general, whether injurious or not. 
 
Definition of Infection 
An infection may be defined as the “growth of an infective organism in or on a 
suitable host, producing clinical signs and symptoms or change in status (e.g. fever, 
delirium, cough, dysuria, purulent exudates)” (American Medical Directors Association, 
2011). Health care-associated infections (HAIs) are defined as infections that an 
individual receives while receiving medical or surgical treatment (HealthyPeople.gov). 
Infections significantly contribute to morbidity and mortality in the long-term care 
setting, such as NHs, and common infection types are urinary tract infections, soft-tissue 
infections, pneumonia and other respiratory tract infections, prosthetic device-associated 





individual is admitted to a hospital for a primary diagnosis of infection, the death rate 
may be as high as 40% (American Medical Directors Association, 2011; Tsan et al., 
2010).  
Significance 
The overall population of seniors age 65 and over is growing, including the 
subpopulation of those with dementia diagnoses; and, many of these seniors will reside in 
NHs, increasing the NH population. Psychotropic medication overuse in NH residents is 
a significant problem. The risk of increased morbidity or mortality is considerably greater 
when psychotropics are administered to NH residents diagnosed with a form of dementia; 
specifically, psychotropic medications are associated with many negative health 
outcomes including falls and infections, and continued usage would place more NH 
residents at risk, relative to the population growth.  
 
Aims and Hypotheses 
Aim 1: Examine and compare psychotropic drug usage in NH residents between 
2011 and 2013 
To address this aim, a descriptive analysis and chi-square tests of national MDS data 
from 2011 and 2013 were performed. 
Hypothesis 1: The distributions of psychotropic medications differ between the 
assessment years 2011 and 2013. 
Aim 2: Determine the association between psychotropic medication usage and risks 





To address this aim, logistic regression analyses of data from 2013 were performed to test 
each of the two hypotheses below: 
Hypothesis 2: Controlling for resident and facility characteristics, residents 
receiving psychotropic medications will have an increased risk for falls than those 
not receiving psychotropic medications. 
Hypothesis 3: Controlling for resident and facility characteristics, residents 
receiving psychotropic medications will have an increased risk for infections than 
those not receiving psychotropic medications. 
Potential Contributions 
This dissertation was the first to use longitudinal MDS and OSCAR/CASPER 
data to examine psychotropic medications at a national level, and this study included all 
four classes of psychotropic medications (antipsychotic, antidepressant, antianxiety, and 
hypnotic). This dissertation examined the prevalence of psychotropic medication use in 
NHs across the nation and the associated fall and infection risks for NH residents. As 
such, it was the first to use national MDS data to explore the associations of psychotropic 
medication use with falls and infections among U.S. NH residents. 
A better understanding of the link between psychotropic medications and falls or 
infections can inform clinical practice and policy. This study addresses the goals of the 
CMS to reduce psychotropic medication use in NH residents with dementia. Moreover, 
the proposed study is in line with the IOM plan to improve the quality of care in NHs and 






Chapter 2 – Review of the Literature 
This chapter describes the review of the literature pertinent to the purpose of this 
dissertation, the association of psychotropic medication and nursing sensitive outcomes, 
falls and infections (Hoke & Guarracino, 2016; Micik et al., 2013). This is a 
comprehensive review of the literature. The chapter is organized in the following manner: 
First, the search strategy for the literature relevant to the use of psychotropic medications 
among NH residents and falls and infections is described. Second, a synthesis of the 
literature relevant to falls is provided. Third, the literature relevant to the use of 
psychotropic medications among NH residents and infections is presented and 
summarized. Then the gaps found therein are outlined. Last, the potential contributions of 
this dissertation to address any of those gaps are described. 
Literature Review Methods 
A search of the literature was conducted using Ovid MEDLINE, PubMed, 
Embase, and CINAHL databases. For the search of the databases, a combination of 
Medical Subject Headings (MeSH) terms and keyword terms were utilized with the 
Boolean Operator “OR” for four separate searches. The first search included the terms of 
“psychotropic drugs” (MeSH), “psychotropic drug” (keyword), “antipsychotic agents” 
(MeSH), “antipsychotic” (keyword), “antidepressive agents” (MeSH), “antidepressant” 
(keyword), “anti-anxiety agents” (MeSH), “antianxiety” (keyword), “hypnotics and 
sedatives” (MeSH), or “hypnotic” (keyword). The second search included the terms of 





(MeSH). The third search included the terms of “accidental falls” (MeSH) or “fall” 
(keyword). The fourth search included the terms of “infection” (MeSH) and “infection” 
(keyword). Using the “AND” Boolean Operator, the resulting search sets for 
psychotropic drugs and NHs were then combined with fall and infection separately to 
examine the intersection of articles between the four search sets: 
 psychotropic drug results AND NH results AND fall results 
 psychotropic drug results AND NH results AND infection results 
Although only the Ovid MEDLINE and PubMed databases utilize the MeSH 
controlled vocabulary for indexing of articles (Lu, Kim, & Wilbur, 2009), all of the same 
terms were also employed in the Embase and CINAHL databases so that all relevant 
articles might be captured in the searches. The searches were limited to the English 
language, and articles that were letters, comments, or on non-relevant topics were 
excluded. The time period for article selection was from 1989 to present, so as to capture 
the relevant literature following the OBRA of 1987. For each study found, the following 
data were abstracted: study design, time period for data collection, country of research, 
number of facilities, sample size, psychotropic drug type examined, source of drug data, 
source of outcome data, mean age of sample, and gender distribution of sample. Also, the 
covariates included in each study were examined.  
Literature Review Results 
Based on the inclusion and exclusion criteria, 14 relevant studies were found 
examining associations between psychotropic medication administration in NHs and 





In Table 2, the 14 fall studies are presented in chronological order followed by the 
infection study.  
The 15 selected articles are synthesized and presented using a narrative approach. 
The characteristics of the studies are provided, and the results from the articles are 
discussed regarding the type of psychotropic drug investigated and the risk of falls or 
infections. Because the researchers of several of the studies presented their results of the 
drug classes in aggregate, or they initially combined two medication classes as a single 
variable for inclusion into the analysis, the results are presented based on the number of 
psychotropic medication classes (antipsychotic, antidepressant, antianxiety, hypnotic) 
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collection
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Number of facilities 437 81 1,174 2 1 2 na
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Literature on Falls and Psychotropic Medication Usage among Nursing Home 
Residents 
Study Characteristics 
Of the fourteen articles reviewed, twelve were cohort studies and two were case-
control studies. Of the cohort studies, seven were prospective ((Echt et al., 2013; Hien et 
al., 2005; Neutel, Perry, & Maxwell, 2002; Nygaard, 1998; Ruthazer & Lipsitz, 1993; 
Sterke et al., 2012; Thapa, Gideon, Fought, & Ray, 1995). In addition to the prospective 
cohort, Neutel et al. (2002) also incorporated a second part to the study that utilized a 
case-crossover design. Five studies were retrospective cohort (Agashivala & Wu, 2009; 
Arfken, Wilson, & Aronson, 2001; Avidan et al., 2005; Ray, Thapa, & Gideon, 2000; 
Thapa, Gideon, Cost, Milam, & Ray, 1998). Two studies were retrospective case-control, 
with one utilizing case-crossover design (Berry et al., 2011) and the other utilizing 
matched-pair design (Mustard & Mayer, 1997). 
Researchers in six of the fourteen studies examined only a single type of 
psychotropic medication, specifically antidepressant (Arfken et al., 2001; Berry et al., 
2011; Ruthazer & Lipsitz, 1993; Thapa et al., 1998), antianxiety (Ray et al., 2000), and 
hypnotic (Avidan et al., 2005). One group examined antipsychotic, antidepressant, and 
antianxiety medications (Echt et al., 2013). Seven studies examined all four types of 
psychotropic medication (Agashivala & Wu, 2009; Hien et al., 2005; Mustard & Mayer, 





The characteristics of the reviewed studies were varied. In eight of the 14 studies, 
the investigators utilized data from the 1990s (Arfken et al., 2001; Mustard & Mayer, 
1997; Neutel et al., 2002; Nygaard, 1998; Ray et al., 2000; Ruthazer & Lipsitz, 1993; 
Thapa et al., 1998; Thapa et al., 1995), and only three studies were conducted with data 
from the last 10 years (Berry et al., 2011; Echt et al., 2013; Sterke et al., 2012). Nine of 
the 14 studies were conducted in the U.S. (Agashivala & Wu, 2009; Arfken et al., 2001; 
Avidan et al., 2005; Berry et al., 2011; Echt et al., 2013; Ray et al., 2000; Ruthazer & 
Lipsitz, 1993; Thapa et al., 1998; Thapa et al., 1995), with the other five studies 
conducted in Canada (Mustard & Mayer, 1997; Neutel et al., 2002), Norway (Nygaard, 
1998), Australia (Hien et al., 2005), and the Netherlands (Sterke et al., 2012). The 
number of facilities included ranged from one to 1,174 sites, and the sample sizes ranged 
from 118 to 34,163 seniors. The data collection period for all of the studies ranged from 
one month to five years. In one study the investigators utilized the MDS (Avidan et al., 
2005) in another study the investigators utilized the National Nursing Home Survey 
(NNHS) (Agashivala & Wu, 2009), and in the other 12 studies investigators utilized 
some form of chart review for obtaining medication data. Also apart from those two 
studies where large existing datasets were utilized, the primary source of fall outcome 
data was incident reports, with some adding chart review to abstract falls data. The mean 
age of the study participants ranged from 81 to 89 years of age, and the study samples 





Study results for all four psychotropics 
Of the 14 articles, researchers in seven of the studies examined all four types of 
psychotropic medications (Agashivala & Wu, 2009; Hien et al., 2005; Mustard & Mayer, 
1997; Neutel et al., 2002; Nygaard, 1998; Sterke et al., 2012; Thapa et al., 1995). 
However, these researchers applied different approaches to their investigations, and the 
results differed across the studies.  
Agashivala and Wu (2009) differentiated between potentially appropriate and 
inappropriate psychotropic medication as per the Beers’ criteria (Fick et al., 2003). They 
used data from the 2004 NNHS and found that NH residents who received potentially 
inappropriate psychotropic medications were at a 17% greater risk for falls than those 
receiving other psychotropic medications and at a 37.6% greater risk for falls than those 
not receiving psychotropic medications. According to the NNHS data, approximately 
17% (or 2,300) of the surveyed seniors living in NHs were receiving potentially 
inappropriate psychotropics. 
Thapa et al. (1995) examined the four psychotropics and their association with 
recurrent falls in independently ambulatory NH residents. They found that regular use of 
psychotropic medication was attributed to 36% of the falls (fall rate of 204 per 100 
person-years and recurrent fall rate of 54.9 per 100 person-years). Regular users of 
psychotropic were found to be at twice the risk of recurrent falls than nonusers (incidence 
density ratio = 1.97). It was also found that among regular psychotropic medication users, 
having five additional risk factors (age ≥ 75, ≥ four impaired activities of daily living, in 





impairment, fall history in 90 days prior to assessment) increased the risk of recurrent 
falls tenfold (rate of 21.4 to 231.5 per 100 person-years). 
Sterke et al. (2012) examined the dose-response relationship between 
psychotropic medications and falls for NH residents with dementia. They found that all 
four psychotropic medications were associated with increased risk for falls (antipsychotic 
hazard ratio [HR] = 1.53, antidepressant HR = 2.28, antianxiety HR = 1.60, hypnotic HR 
= 1.50). Significant dose-response relationships were also reported (antipsychotic HR = 
2.78, antidepressant HR = 2.84, antianxiety HR = 1.60, hypnotic HR = 2.58). Even at 
25% of the defined daily dose, as defined by the WHO (World Health Organization, 
2013), the psychotropic medications were associated with increased risk for falls. Greater 
dosages and/or combinations significantly raised the already increased fall risk. 
Hien et al. (2005) examined the association of risk for falls in NH residents from 
usage of atypical antipsychotics (specifically olanzapine and risperidone), 
hypnotic/antianxiety medication (grouped together), and antidepressants versus typical 
antipsychotics. In the analysis results, only olanzapine and antidepressants were 
significant for fall risk (HR = 1.74 and 1.45, respectively). Risperidone, typical 
antipsychotics, and hypnotic/antianxiety medications were not significantly associated 
with falls. 
In one of the smaller studies conducted in Norway (n = 118), Nygaard (1998) 
examined all four psychotropics and the risk of falls, and he found that no medication 
was individually associated with the risk of falling. However, mental impairment and 





either of those was coupled with a psychotropic medication, then that medication was 
significantly associated with an increased risk of falling. For example, mentally impaired 
residents taking hypnotics or antianxiety medications had a significantly higher risk of 
falling (OR = 4.0).  
The last two groups of researchers examined medication use in general (all four 
psychotropic drugs in addition to others) and the risk for falls (Mustard & Mayer, 1997; 
Neutel et al., 2002). Neutel et al. (2002) had two components to their study: 1) a 
prospective cohort examining risk of falls with medication usage and 2) a case-crossover 
design to estimate fall risk when initiating a new antipsychotic or benzodiazepine. 
Similar to Nygaard (1998), they found that a medication individually was not associated 
with falls. However, polypharmacy was found to increase risk of falling. Residents taking 
five to nine medications were at a fourfold risk for falls, and those taking ten or more 
medications had a six fold increased risk for falls. In the case-crossover portion of the 
study, residents initiating new prescriptions for antipsychotics and benzodiazepines had a 
significantly increased risk for falls (OR = 11.4). 
In the study by Mustard and Mayer (1997), the outcome of falls was defined as an 
injurious fall resulting in a hospital admission and matched-pair cases and controls 
(matched by age, sex, dependency level, duration of residence, and underlying disorder) 
were compared. The researchers found that NH residents receiving antianxiety/hypnotic 
medications (grouped together) or antipsychotic medications had an increased number of 
injurious falls when compared to NH residents not receiving any (antianxiety/hypnotics 





Possible explanations for the differences between the above seven studies are the 
usage of multiple psychotropics and varying time lengths of usage amongst the NH 
residents. Also, Nygaard (1998) and Neutel et al. (2002) had the smallest sample sizes, 
and that may have affected their ability to detect significant associations between the 
individual psychotropic medications and risk for falls. Additionally, researchers in the 
seven studies indicated the intent to examine all four types of psychotropics, but the 
individual medications and dosages were not identified. The actual medications that were 
studied may have factored in the studies’ results. 
Study results for three psychotropics 
In one study by Echt et al. (2013), researchers examined the initiation or increased 
dosage of antipsychotic, antidepressant, and antianxiety medications and risk for falls. 
These researchers found that new prescriptions and increased dosages of all three types of 
psychotropics were associated with an increased risk for falls (antipsychotic 18.4 per 
1,000 person-days, antidepressant 13.7 per 1,000 person-days, & antianxiety 15.0 per 
1,000 person-days as compared to 4.1 per 1,000 person-days for those with no change in 
medication). These researchers found that the highest risk was the first day following the 
new or increased dosage of medication, but an elevated risk still appeared three to four 
days prior to and up to seven days following a new or increased prescription. 
Antidepressant 
Researchers in four of the 14 studies examined just antidepressant medication and 
risk for falls (Arfken et al., 2001; Berry et al., 2011; Ruthazer & Lipsitz, 1993; Thapa et 





serotonin receptor inhibitor (SSRI), non-SSRI, tricyclic, and trazodone. Among these 
four studies, the results were varied in antidepressant medication usage and their 
association with risk for falls. 
For example, Berry et al. (2011) found that SSRI antidepressants were not 
associated with an acute increased risk of falling but that non-SSRI antidepressant 
medications were associated with an acute risk of falls (OR = 4.7). These researchers 
found that within two days of a new prescription or an increased dosage of a non-SSRI 
medication, there was a fivefold increased risk of falling. 
However, Thapa et al. (1998) found that those receiving SSRI medication had an 
80% higher risk of falls (adjusted rate ratio [ARR] = 1.8) and a 70% higher risk of 
injurious falls (ARR = 1.7) than nonusers. Similar to Thapa et al. (1998), Arfken et al. 
(2001) found that NH residents receiving SSRI medication had a significant risk of falls 
(OR = 2.68) and risk of injurious falls (OR = 2.42). The risk of falls from SSRIs was 33% 
greater than those receiving non-SSRIs and 60% greater than those not receiving 
antidepressants. Also, those receiving SSRI medication were eight times more likely to 
experience an injurious fall than those not receiving antidepressant medications. 
Thapa et al. (1998) also found that NH residents receiving tricyclic antidepressant 
medication had double the risk of falls (ARR = 2.0) and a 30% higher risk of injurious 
fall (ARR = 1.3) than nonusers. Those receiving trazodone medication had a 20% higher 
risk of falls (ARR = 1.2) and 10% higher risk of injurious falls (ARR = 1.1) than 





increased with increasing dosages. Also, the elevated risk of falls for SSRI and tricyclic 
medication remained throughout the course of antidepressant therapy. 
Ruthazer and Lipsitz (1993) examined gender related differences and found that 
women receiving SSRI medication had more than three times the rate of falls than 
women taking tricyclic medication (53% versus 14%). Also, women receiving SSRI or 
tricyclic antidepressants were at significantly greater risk of falls than women not 
receiving antidepressant medication at all (OR = 1.95). In contrast, men receiving any 
antidepressant medication had a one month fall rate that was actually lower than men not 
receiving any antidepressants. 
The differences and similarities amongst the four studies in this group are not 
readily explained by differences in sample size, number of facilities, or source of drug 
data or falls data. Also, the individual SSRI, non-SSRI, or tricyclic medications are not 
all listed in each study, so the actual antidepressants used in the various studies may have 
had some impact. In the study by Ruthazer and Lipsitz (1993), the researchers explained 
that a possible reason for the increased falls for women and not men may be explained by 
the effect of antidepressants combined with the characteristics of women in NHs (e.g. 
women with less strength in lower extremities than men). 
Antianxiety 
One group of researchers examined the association of only antianxiety medication 
(short-, intermediate-, long-acting benzodiazepines) and risk of falls (Ray et al., 2000). 
Ray et al. (2000) found that users of benzodiazepines had a 44% higher rate of falls than 





associated with a greater risk of falls (ARR = 2.96), but a 30% elevated risk of falls 
persisted for 30 days after medication initiation (ARR = 1.30). Increasing dosages were 
also linked to the increase in the rate of falls (ARR = 1.30 to 2.21). Long-acting 
benzodiazepines were associated with higher risk of falls as compared to intermediate- or 
short-acting benzodiazepines. 
Hypnotic 
In the last study, researchers examined hypnotic use and its association with falls 
and hip fractures in NH residents (Avidan et al., 2005). This is the only study found in 
which the researchers used MDS data to examine any psychotropic drug use and linkages 
to falls in U.S. NHs, and they found that hypnotic use had no association with falls. In 
fact, those with insomnia and not using hypnotics had a higher risk of falls than those 
using hypnotics (OR = 1.90 vs OR = 1.29, respectively). Likewise, those who still had 
insomnia despite using hypnotics had greater risk of falls (OR = 1.54). The researchers 
utilized data from two years (2001-2002) with a sample size of 34,163 from 437 
facilities, so the power of the study would not have been the cause for lack of association 
between hypnotic usage and falls. It was unclear amongst the researchers in this study as 






Literature on Infections and Psychotropic Medication Usage among Nursing Home 
Residents 
Study characteristics 
Only one study was found that examined the associations between psychotropic 
medication usage and infection in NH residents, and it was a retrospective cohort analysis 
in which the researchers used propensity score matching (Aparasu, Chatterjee, & Chen, 
2013). In the study, Aparasu et al. (2013) examined the use of typical/conventional versus 
atypical antipsychotics. Although published in 2013, the retrospective data were from 
2001 to 2003. 
The study design included the use of two samples: a) 49,904 participants in the 
unmatched cohort and b) 7,218 participants in the matched cohort. The NHs were from 4 
states (Texas, New York, California, and Florida). The source of data for antipsychotic 
medication administration and infection (i.e. pneumonia) was claims data for Medicare 
and Medicaid dual eligible beneficiaries. The mean age for both sample cohorts was 83 
years, and the study samples were predominantly female. The researchers examined 
typical versus atypical antipsychotics and their associated risks for pneumonia in NH 
residents. They compared the risks between the two types to determine if they were 







The researchers found no significant difference in the risk of pneumonia between 
users of typical/conventional and atypical antipsychotic medications (HR = 1.24, p = 
0.12). The researchers did not evaluate the risk of pneumonia associated with the use of 
other antipsychotic drugs.  
While not specific to the NH setting, six closely related studies were found 
(Dublin et al., 2011; Gau et al., 2010; C. Huang et al., 2014; Knol et al., 2008; Rogers et 
al., 2013; Trifiro et al., 2010). Researchers examined multiple infection types in one 
study (C. Huang et al., 2014), Clostridium Difficile in another study (Rogers et al., 2013), 
and pneumonia in the remaining four studies (Dublin et al., 2011; Gau et al., 2010; Knol 
et al., 2008; Trifiro et al., 2010). These six studies were conducted amongst seniors in 
general (e.g. community dwelling, inpatient, and outpatient). 
C. Huang et al. (2010) found that the hypnotic drug Zolpidem was associated with 
an increased risk of infection among patients with sleep disturbance. This study included 
28 possible types of infections (e.g. bronchitis, septicemia, and cellulitis). Rogers et al. 
(2013) found that depression and/or use of antidepressants was associated with 
Clostridium Difficile infection in older adults. Of the four studies in which researchers 
examined risk for pneumonia, three of them included antipsychotic medication usage 
(Gau et al., 2010; Knol et al., 2008; Trifiro et al., 2010), and the other included the use of 
the antianxiety drug benzodiazepine (Dublin et al., 2011). Trifiro et al. (2010) found that 
antipsychotic medication use was associated with a dose-dependent risk for community-





elderly adults was associated with an increased risk for infection, particularly the period 
shortly after initiation of drug therapy.  Gau et al. (2010) found that atypical antipsychotic 
usage was associated with an increased risk for community-acquired pneumonia among 
hospitalized elderly patients in a rural community. Dublin et al. (2011) found that 
benzodiazepines were not associated with an increased risk for pneumonia. These six 
studies were significant in identifying the gap of knowledge and growing interest in 
examining the associations between psychotropic medication use and infections. 
Gaps in the literature 
The overall consensus from the studies in the review of the literature is that usage 
of all psychotropic medications (antipsychotic, antidepressant, antianxiety, hypnotic) in 
U.S. NH residents is correlated with increased risk for falls, but the majority of the data 
from the fourteen studies are greater than 15 years old, and some are greater than 20 
years old. Only two of the studies were conducted in both the U.S. and completed using 
data obtained within the last ten years. 
In the search for studies that involve psychotropic medication usage among NH 
residents and the association to infections, the current body of literature was found 
lacking. Only one such study was found, and it utilized data from over a decade ago in 
the U.S. In addition, the researchers found no associations between the two classes of 
antipsychotics and pneumonia. Six other studies were found wherein researchers 
examined the associations between various psychotropics and risk for different 
infections. However, these studies were not focused on NH residents, and therefore, there 





Very little literature was found for these two important nursing sensitive 
outcomes among U.S. NH residents. Much of what could be found was outdated or 
limited in scope. Researchers from only one study utilized the MDS as a source of data 
for their analyses. Furthermore, none of the researchers from the above NH studies 
controlled for facility level characteristics in their analyses. Yet, facility characteristics 
have been shown in research to influence health quality and outcomes. For instance, 
nurse staffing levels in both NHs and hospitals have been found by researchers to be 
strongly and consistently associated to quality (Castle & Anderson, 2011; Needleman, 
Buerhaus, Mattke, Stewart, & Zelevinsky, 2001). Other researchers reported that greater 
nursing staffing could significantly decrease adverse health outcomes in NH residents 
(Konetzka, Stearns, & Park, 2008). 
This highlights a gap in research literature for studies that combine the 
investigation of psychotropic drug usage and nursing care. Such studies were not found in 
this literature review. 
Addressing the gaps 
To address the gaps found in the current body of literature, this dissertation 
utilized more current data at a national level. The data were from a national NH MDS 
data set, and this study examined four types of psychotropic medications and associations 
with risk for falls or infections. In addition to the influence of psychotropics, this 
dissertation provided unique contributions into the research of nursing care and its 





Chapter 3 – Methods 
This chapter describes the methods used for this dissertation, and it is organized in 
the following manner. First, the data sources that were utilized for the dissertation are 
discussed. Second, the study design, including sample selection and unit of analysis is 
outlined. Third, the independent and outcome variables of interest and covariates for the 
study are presented. Next, the statistical analyses that were used in the dissertation are 




The NH data used for this study were obtained from the MDS 3.0 version and 
OSCAR/CASPER for years 2011 and 2013. Three out of four quarters of medication use 
data were missing for 2012 from the provided dataset, so data from that year were not 
able to be included in this study. More recent data (post 2013) were not available and 
therefore were also not included. All sources of data were standardized instruments that 
were instituted and implemented by CMS for certified NHs (Huybrechts et al., 2012; Mor 
et al., 2011).  
The MDS is a health assessment tool for NH residents, and it provided resident 
health characteristics for this study, processes of care (i.e., psychotropic usage) and 
outcomes (i.e., falls or infections). The MDS assessments are completed at admission, 
quarterly, annually, and upon any significant change in resident health status (Rahman & 





items have a look-back period of seven days, and the fall item has a look-back period of 
up to 90 days (since admission or last assessment, whichever is more recent). All 
infections have a look-back period of seven days, except for urinary tract infection, which 
has a look-back period of 30 days (Hill‐Westmoreland & Gruber‐Baldini, 2005; Rahman 
& Applebaum, 2009; Saliba & Buchanan, 2008). After the initial development, a second 
version of the MDS (2.0) was introduced in 1995 and a third version (3.0) was 
implemented October 1, 2010. This study utilized assessment data from MDS 3.0 and 
therefore only include years 2011 and 2013.  
The MDS 3.0 version was submitted to extensive analysis and was developed to 
improve upon the previous two versions. In a national evaluation study, the psychometric 
analysis included interrater reliability testing, with Kappa statistics used as measures of 
interrater reliability. In the evaluation study, a research nurse was considered to be the 
gold standard (GS) for raters. If the psychometric testing involved interrater reliability 
between two research nurses, the notation was indicated by GS to GS, meaning that a 
gold standard rater was tested against another gold standard rater (Saliba & Buchanan, 
2008). 
Research nurses attended two 4-day training sessions, and each then returned to 
their respective facilities. When data collection began, each research nurse completed 
MDS 2.0 and MDS 3.0 assessments on NH residents within an allotted time period. The 
assessments from the research nurse were compared to those of another research nurse 
(GS to GS), and Kappa values were computed. The researchers found the MDS 3.0 items 





Overall the item reliabilities were often greater in MDS 3.0 than found in previous 
studies for MDS 2.0 (Saliba & Buchanan, 2012). 
The interrater results between assessors in examining the falls and infection items 
were excellent. For the falls data section, the interrater reliability score from research 
nurse to research nurse (GS to GS) was Kappa = 0.967. The infection items also received 
excellent reliabilities (multidrug-resistant organism – 100% agreement, pneumonia – 
Kappa = 0.930, urinary tract infection – Kappa = 0.962, wound infection – Kappa = 
0.922) (Saliba & Buchanan, 2008). The septicemia infection item was not listed in the 
evaluation study results. 
The interrater results between assessors for the medication data section was also 
exceptional from GS to GS (Kappa = 0.978). Additionally, all four of the psychotropic 
medications individually received excellent reliability results from GS to GS 
(antipsychotic – Kappa = 0.983, antianxiety – Kappa = 0.949, antidepressant – Kappa = 
0.983, hypnotic – Kappa = 0.958) (Saliba & Buchanan, 2008).  
OSCAR/CASPER is a standardized system for NH regulatory surveys that are 
completed yearly (Mor et al., 2011). The evaluations are conducted in NHs that are 
certified by CMS and are required for reimbursement (Huybrechts et al., 2012). The 
OSCAR/CASPER data includes facility characteristics such size, staffing, structure, and 
aggregate resident characteristics, and the system is maintained by CMS (Huybrechts et 
al., 2012; Kash, Hawes, & Phillips, 2007). 
Reliability studies were conducted using OSCAR data.  In a study using four 





the MDS and OSCAR (N. J. Zhang et al., 2009). These researchers found that most of the 
clinical measures had good overall reliability, but some indicators for administrative data 
were more dependable than others. In another study, researchers found OSCAR data was 
highly reliable in certified bed counts, but had discrepancies in resident census and 
staffing levels (Straker & Center, 1999). 
When linked with the MDS, the OSCAR/CASPER data can be utilized for 
research, but there are some concerns as to its validity and possible ascertainment bias 
(Ryan, Stone, & Raynor, 2004; Straker & Center, 1999). Inconsistencies in staffing level 
reporting, lack of data uniformity, and variation in survey practices have been cited as 
concerns for using OSCAR/CASPER data (Kash et al., 2007; Ryan et al., 2004). Also, 
the new annual data that are entered into the system overwrites the old data, limiting the 
ability to examine historical data. However, there are private companies that obtain and 
store annual data (Ryan et al., 2004). For this dissertation, the historical 
OSCAR/CASPER data were used in the analysis. 
The OSCAR/CASPER system is an important source of national NH data that 
provides characteristics for the facility and residents (Kash et al., 2007). It is also the 
largest single source and the only national source of NH facility data (Straker & Center, 









The design was a retrospective analysis.  
Sample 
Quarterly and annual assessments were based on the date of admission, and a NH 
resident may have had a quarterly but no annual assessment in a given year. Therefore to 
avoid the inadvertent omission of potential observations, individuals eligible for inclusion 
were all NH residents with quarterly and/or annual MDS assessment from years 2011 and 
2013 in facilities that utilize MDS reporting. Admission assessments documented activity 
prior to NH admission, and this study was focused on actions conducted within the NH. 
Therefore, the admission assessments were not included in the analyses. Due to the very 
large size of the overall population, a random 5% sample of the total facilities were taken, 
and all of the quarterly and annual MDS assessments from those selected facilities were 
included for analysis. 
 
Unit of Analysis 
Inferences about people that are based on groups of individuals instead of the 
individuals themselves may lead to serious inaccuracies (Steel & Holt, 1996). Those 
inferences made from the aggregated data are often only weakly supported, and incorrect 
conclusions are very easy to draw from aggregated data (Freedman, 1999). In this 
dissertation, the use of variables from a collective group of NH residents (such as 





use and falls or infections could lead to ecological fallacy (Freedman, 1999; Piantadosi, 
Byar, & Green, 1988; Steel & Holt, 1996). Therefore, all analyses were done at the 
individual NH resident level. 
Variables 
The selection of the variables to include was informed by the literature review. 
Appraisal of the more commonly included covariates from all of the studies aided in 
determining which variables to include (see Appendix A). The variables were grouped 
into categories based on the adapted framework of health care quality: 1) Structure (size, 
location, staffing variables), 2) Process (psychotropic medication administration), 3) 
Resident Characteristics (age, gender, race, functional status, cognitive status, dementia 
diagnosis), and 4) Outcomes (falls, infections).  
Based on this research and the evidence presented in Chapter 2, the structure- 
related covariates for this study include size (defined as bed count), location (defined as 
the state in which the facility resides), and staffing (defined as staffing levels for 
registered nurses [RNs], licensed practical nurses [LPNs], and certified nursing assistants 
[CNAs] and expressed in hours per resident day [HRD]). The three staffing variables 
were recoded as categorical variables with three levels – low, medium, and high. One 
standard deviation from the median value was utilized to determine the cut-off levels for 
high and low, with medium encompassing the range of values in the middle. 
The process-related variable (i.e., the independent variable of interest) for this 
study was psychotropic medication administration. The four classes of psychotropics that 





administration of these psychotropic medications for NH residents was recorded during 
the MDS assessment.   
The outcomes (dependent variables) were falls and infections. The fall variable 
was a dichotomous variable, with responses that indicated the absence or presence of any 
falls since admission or the last assessment. The infection variable was a dichotomous 
variable and was defined as the absence or presence of any or combination of the 
following types of infection: multidrug-resistant organism, pneumonia, septicemia, 
urinary tract infection, or wound infection (other than foot). 
The psychotropic medication data collected in 2011 was a dichotomous response 
(yes/no) for having received a psychotropic medication in the past seven days for each 
type of medication. In April of 2012, the MDS changed the format to inquire as to the 
number of days in the past seven days that the NH resident received a psychotropic 
medication. Therefore, the 2013 medication data were collected as a count of days. Both 
original formats provided by the MDS and new modified formats (as described in the 
next paragraph) were examined for use in the analyses for Aims 1 and 2. Only 2013 data 
were used for the analysis in Aim 2 because they were potentially more informative, due 
to psychotropic medication being re-operationalized with counts (“seven day count”). 
One objective was to explore the distributions resulting from the new count format.  
Using the 2013 psychotropic medication data, additional variables were generated 
as variations to examine medication administration. The first set of new variables 
(“binary response”) were four dichotomous variables that mirrored the format of the 





medication in the past seven days. Due to the irregularity of distribution across the 
number of days, these dichotomized variables were used for the analyses instead of the 
count variables. The next new variable (“none or any”) was a dichotomous variable that 
was delineated by a null response (no psychotropic medication of any type was 
administered) versus an affirmative response (any single or multiple types of 
psychotropic medications were administered).  The last new variable (“combination 
count”) was one that specified the concurrent counts of psychotropics that were 
administered in the past 7 days (none, one, two, three, or all four psychotropics) to assess 
polydrug/polypharmacy. The particulars as to which one or which combination of drugs 
did not matter. 
The resident characteristic covariates for this study included demographic (age, 
gender, and race) and clinical variables (functional status, cognitive status, and dementia 
diagnosis). Functional status was measured from the values of seven MDS items (bed 
mobility, transfer, locomotion on unit, dressing, eating, toilet use, and personal hygiene). 
The selection of the functional status items was guided by the Activities of Daily Living 
– Long Form Scale. Cognitive status was indicated from one MDS item (makes self 
understood). Dementia diagnosis was distinguished as either Alzheimer’s disease or 
Dementia (Non-Alzheimer’s disease and all other forms of dementia). 
The facility level variables were obtained from OSCAR/CASPER. The resident 
level variables from the MDS 3.0 were extracted from quarterly and/or annual 












Size Total number of beds in the NH
(OSCAR/CASPER variable bed_cnt)
Facility
Location State in which the facility is located (SSA State Code)
(OSCAR/CASPER variable ssa_state_cd) 
Facility
Staffing Staffing level of the facility
(RN, LPN, & CNA - hours per resident day grouped as low, medium, or high)





Receipt of psychotropic medications:
antipsychotic; antianxiety; antidepressant; hypnotic
(MDS item numbers N0410A, N0410B, N0410C, N0410D)
(Variations: Binary Response/Seven Day Count/None or Any/Combination Count)
Resident
Age Age group assignments: 65-74; 75-84; 85-94, 95 & older
(MDS item number A0900)
Resident
Gender Male/Female
(MDS item number A0800)
Resident
Race American Indian or Alaska Native; Asian; Black or African American; Hispanic or 
Latino; Native Hawaiian or Other Pacific Islander; White
(MDS item numbers A1000A, A1000B, A1000C, A1000D, A1000E, A1000F)
Resident
Functional Status Activities of Daily Living items - bed mobility, transfer, dressing, locomotion, eating, 
toileting, personal hygiene
(MDS item numbers G0110A, G0110B, G0110E, G0110G,G0110H, G0110I, 
G0110J)
Resident
Cognitive Status Makes self understood
(MDS item number B0700)
Resident
Dementia Diagnosis Alzheimer's Disease; Non-Alzheimer's Disease
(MDS item numbers I4200, I4800)
Resident
Falls Falls - Any since admission or the last assessment
(MDS item number J1800)
Resident
Infections One or more of : multidrug-resistant organism (MDRO); pneumonia; septicemia; 
urinary tract infection (UTI); wound infection (other than foot)
(MDS item numbers I1700, I2000, I2100, I2300, I2500)
Resident
Note:   (NH) Nursing Home                            (SSA) Social Security Administration              (MDS) Minimum Data Set
            (LPN) Licensed Practical Nurse         (CNA) Certified Nursing Assistant                   (RN) Registered Nurse
            (OSCAR) Online Survey Certification and Reporting    










Standard descriptive statistics were completed prior to all multivariate analyses, 
and distributions of all variables were examined using histograms or crosstabs. 
Relationships among key variables were described through bivariate analyses. Chi-square 
tests were used to examine bivariate associations between the categorical variables, and t-
tests were used to examine continuous variables. All data were cleaned and inspected for 
missing values. All analyses were conducted without imputing values for missing data. In 
the subsequent two sections, I describe the data analytic strategies used to evaluate the 
relationships represented in the conceptual framework.  
Data Analysis Aim 1: Examine and compare psychotropic drug usage in nursing 
home residents between 2011 and 2013 
I used descriptive statistics and chi-square tests to address the first aim and test 
the following hypothesis: 
Hypothesis 1: The distributions of psychotropic medications are different 
between the assessment years 2011 and 2013. 
All analyses were completed using StataSE version 14.  
Data Analysis Aim 2: Determine the association between psychotropic medication 
usage and risks of falls and infections for nursing home residents in the United 
States 
I used generalized estimating equations with logistic regression analysis to 





Hypothesis 2: Controlling for resident and facility characteristics, residents 
receiving psychotropic medications will have an increased risk for falls than those 
not receiving psychotropic medications. 
Hypothesis 3: Controlling for resident and facility characteristics, residents 
receiving psychotropic medications will have an increased risk for infections than 
those not receiving psychotropic medications. 
 
To account for repeated measures on multiple, successive annual/quarterly 
assessments that were conducted on the same NH resident, generalized estimating 
equations were utilized for the logistic regression analysis. This method accommodated 
the clustering around the NH resident. All regression analyses were completed using 
StataSE version 14. 
In the analysis, the dichotomous, dependent variable is Yij (falls/infection) for the 
ith resident in the jth facility. The logistic regression model is listed below: 
 P(y) = ____________1____________           












 In the equation, the X represents the independent variable; β0 is the intercept; and 
β1, β2, and β3 are the coefficients for the independent variables. This model also includes 







The sample for Aim 1 of this study incorporated 5% of NHs and all residents 
within the selected NHs that had quarterly and annual MDS assessments for years 2011 
and 2013. For Aim 2, only data from 2013 were used. Power analysis was conducted 
using StataSE version 14, and the estimated sample size necessary to detect an effect was 
determined to be 105,071 observations. This was calculated using a power of 90%, a 
significance level of 5%, an effect size of 1%, and a two-sided test. When the effect size 
was changed to 5%, 10%, and 25% (with the other parameters remaining the same), the 
estimated sample sizes were 4199, 1047, and 165 respectively. To the best of this 
author’s knowledge, current literature could not provide standards for a clinically 
meaningful effect size, so multiple iterations were conducted. Also, Long & Freese 
(2006) posited that a minimum sample size of 500 would be adequate for most logistic 
regression analyses (Long & Freese, 2006). The sample size for Aim 1 of this dissertation 
was approximately 363,000 NH resident observations, and the sample for Aim 2 was 
approximately 184,000 NH resident observations. As such, there was sufficient power to 
identify associations in the analyses.  
 
Limitations 
The data for this study were retrospective, and data collection was completed 
before the start of this study. A limitation of the MDS assessment data was that the look-
back period for the administration of psychotropic medication was only seven days. This 





more complete understanding of psychotropic medication usage on a daily basis. Also, 
the data were subject to potential self-report bias from clinicians that conducted and 
submitted the annual assessments. Nevertheless, the MDS assessments were regulated by 
the CMS and open to CMS audit. Incorrect or inaccurate reports were subject to 
penalties, and the CMS reimbursement schedule was a monetary incentive for NHs to 
submit accurate psychotropic drug usage and fall data. Therefore, the MDS dataset was 
appropriate for this study. 
 
Protection of Human Subjects 
Risks to the Human Subjects 
Human Subjects Involvement and Characteristics 
The Institutional Review Board (IRB) is responsible for the safety and welfare of 
human subjects in research that involves human subjects. This study was considered 
exempt by the IRB under category 4 (45 CFR 46 .101(b) (4)). This dissertation was a 
secondary analysis of two large datasets. The human subjects for this study were 
residents in national NHs that are certified by CMS. The study utilized data that were de-
identified, with no direct contact with the human subjects (i.e. residents). However, IRB 
approval/exemption was still obtained prior to any data acquisition and analysis. 
Sources of Materials 
The data for this study were de-identified resident assessment level information 





this study were previously acquired by the RAND Corporation for the Prevention of 
Nosocomial Infections & Cost-Effectiveness in Nursing Homes (PNICE-NH) study 
(R01-NR-013687). The CMS Data Use Agreement (DUA) that governed the data 
protection is DUA #25525, and my name was listed as a Custodian with approved access. 
Therefore, no direct contact with the human subjects was part of this study. 
Potential Risks 
There was only minimal potential risk to the subjects (i.e. NH residents), and this 
risk consisted of disclosure of their identity. However, per the DUA, subject identifiers 
were never part of the datasets obtained for this study. The results were presented in 
aggregate, and no attempt were made to identify individual NH residents. 
Adequacy of Protection against Risks 
Recruitment and Informed Consent 
Recruitment and informed consent were not applicable to this study since existing 
databases were utilized. It was not be possible to acquire consent from the subjects, 
which numbered in the hundreds of thousands. Consequently, a request for exemption of 
informed consent was submitted to the Columbia University IRB, and all of their 
requirements were met. 
Protection against Risk 
As noted above, the NH residents were protected from risk of loss of 





the MDS and the facility data from OSCAR/CASPER were stored in electronic files on 
Columbia University computers using password protection and encrypted servers. 
Potential Benefits of the Proposed Research to Subjects and Others 
Direct benefit for the current NH residents was not incorporated into this 
proposed study. However, the potential benefits for future NH residents exist in the 
knowledge that may be gained from understanding the associations between psychotropic 
medication usage and falls or infection. This study also produced evidence concerning 
the prevalence of psychotropic medication usage in U.S. NHs. This knowledge may be 
important for prospective policies that can improve the safety and quality of care for 
residents in NHs, with respect to psychotropic medication treatment. The risks to the 
subjects were reasonable when compared to the potential benefits to NH residents. 
Importance of Knowledge to be Gained 
The dissertation provided information to health care providers and policymakers 
that may be helpful in creating guidelines and treatment protocols that improve care for 
NH residents and minimize risks from psychotropic medications. The benefits to be 
gained in this study far outweighed the risks. 
Inclusion of Women and Minorities 
Women and minorities were included in this dissertation. The residents in the 
MDS databases were from CMS-certified NHs nationwide, and this population included 
both genders and all minorities, at varying levels. According to demographic 





residents were White, with various minorities comprising the remaining 21%. This study 
did not utilize any inclusion or exclusion criteria based on gender or ethnicity. 
Inclusion of Children 
This study was designed to examine the associations between psychotropic 
medications and falls in elderly NH residents, and the minimum age for inclusion in the 



















Chapter 4 – Results 
This chapter provides a detailed summary of the results from the descriptive 
analysis and generalized estimating equations with logistic regression. First, the 
characteristics of the samples from 2011 and 2013 are discussed. Next the descriptive 
statistics and bivariate analyses are presented. Then, the results for Aims 1 and 2 with 
their corresponding hypotheses are discussed. 
 
Sample Characteristics 
The sample from year 2011 contained 178,462 observations, and the sample from 
year 2013 contained 184,056 observations. The majority of the observations were from 
white females over the age of 85. Approximately 71% of the observations for both years 
were from NH residents with some form of dementia (Alzheimer’s disease, non-
Alzheimer’s dementia). Approximately half of the observations for both years were from 
residents requiring extensive assistance for all of the ADLs, with the exception of eating. 
Detailed characteristics of the NH residents from the two sample years are provided in 











Table 4  Resident Characteristics 
 
Gender
Male 46,902 26.3% 50,063 27.2% 96,965 26.7%
Female 131,560 73.7% 133,993 72.8% 265,553 73.3%
Total 178,462 100% 184,056 100% 362,518 100%
Race
White 141,087 79.1% 146,198 79.4% 287,285 79.2%
Black 20,275 11.4% 21,431 11.6% 41,706 11.5%
Hispanic 9,006 5.0% 9,568 5.2% 18,574 5.1%
Asian 2,546 1.4% 2,862 1.6% 5,408 1.5%
American Indian/Alaskan Native 527 0.3% 504 0.3% 1,031 0.3%
Native Hawaiian/Pacific Islander 149 0.1% 173 0.1% 322 0.1%
Multi Race 599 0.3% 516 0.3% 1,115 0.3%
Unknown 4,273 2.4% 2,804 1.5% 7,077 2.0%
Total 178,462 100% 184,056 100% 362,518 100%
Age - Year Categories
65-74 29,123 16.3% 32,328 17.6% 61,451 17.0%
75-84 58,528 32.8% 58,580 31.8% 117,108 32.3%
85-94 74,759 41.9% 76,330 41.5% 151,089 41.7%
95 & older 16,052 9.0% 16,818 9.1% 32,870 9.1%
Total 178,462 100% 184,056 100% 362,518 100%
Cognitive Status: Makes Self Understood
Understood 93,493 52.5% 99,860 54.3% 193,353 53.4%
Usually Understood 40,850 22.9% 41,971 22.8% 82,821 22.9%
Sometimes Understood 25,287 14.2% 24,962 13.6% 50,249 13.9%
Rarely/Never Understood 18,477 10.4% 16,956 9.2% 35,433 9.8%
Total 178,107 100% 183,749 100% 361,856 100%
Alzheimer's Disease
No 141,610 79.4% 148,260 80.6% 289,870 80.0%
Yes 36,813 20.6% 35,756 19.4% 72,569 20.0%
Total 178,423 100% 184,016 100% 362,439 100%
Non-Alzheimer's Dementia
No 88,329 49.5% 89,110 48.4% 177,439 49.0%
Yes 90,101 50.5% 94,886 51.6% 184,987 51.0%
Total 178,430 100% 183,996 100% 362,426 100%
2011 2013 Total






ADL Self Performance Measures
Bed Mobility
Independent 28,784 16.1% 22,500 12.2% 51,284 14.1%
Supervision 12,503 7.0% 15,326 8.3% 27,829 7.7%
Limited Assistance 23,124 13.0% 21,580 11.7% 44,704 12.3%
Extensive Assistance 85,379 47.8% 100,514 54.6% 185,893 51.3%
Total Dependence 28,654 16.1% 24,123 13.1% 52,777 14.6%
Total 178,444 100% 184,043 100% 362,487 100%
Transfer (Between Surfaces)
Independent 21,706 12.2% 18,014 9.8% 39,720 11.0%
Supervision 14,403 8.1% 16,856 9.2% 31,259 8.6%
Limited Assistance 24,898 14.0% 23,389 12.7% 48,287 13.3%
Extensive Assistance 76,896 43.1% 88,386 48.0% 165,282 45.6%
Total Dependence 40,544 22.7% 37,400 20.3% 77,944 21.5%
Total 178,447 100% 184,045 100% 362,492 100%
Locomotion (On Unit)
Independent 34,144 19.1% 27,676 15.0% 61,820 17.1%
Supervision 25,400 14.2% 30,131 16.4% 55,531 15.3%
Limited Assistance 25,789 14.5% 25,730 14.0% 51,519 14.2%
Extensive Assistance 41,953 23.5% 51,222 27.8% 93,175 25.7%
Total Dependence 51,141 28.7% 49,197 26.7% 100,338 27.7%
Total 178,427 100% 183,956 100% 362,383 100%
Dressing
Independent 11,102 6.2% 9,410 5.1% 20,512 5.7%
Supervision 9,702 5.4% 10,699 5.8% 20,401 5.6%
Limited Assistance 26,383 14.8% 24,355 13.2% 50,738 14.0%
Extensive Assistance 93,173 52.2% 107,154 58.2% 200,327 55.3%
Total Dependence 38,082 21.3% 32,369 17.6% 70,451 19.4%
Total 178,442 100% 183,987 100% 362,429 100%
Eating
Independent 57,442 32.2% 48,774 26.5% 106,216 29.3%
Supervision 55,799 31.3% 67,200 36.5% 122,999 33.9%
Limited Assistance 18,814 10.5% 20,183 11.0% 38,997 10.8%
Extensive Assistance 23,395 13.1% 28,166 15.3% 51,561 14.2%
Total Dependence 22,995 12.9% 19,722 10.7% 42,717 11.8%
Total 178,445 100% 184,045 100% 362,490 100%
Toileting
Independent 16,584 9.3% 13,749 7.5% 30,333 8.4%
Supervision 10,911 6.1% 12,554 6.8% 23,465 6.5%
Limited Assistance 20,956 11.7% 19,701 10.7% 40,657 11.2%
Extensive Assistance 82,582 46.3% 97,872 53.2% 180,454 49.8%
Total Dependence 47,410 26.6% 40,170 21.8% 87,580 24.2%
Total 178,443 100% 184,046 100% 362,489 100%
Personal Hygiene
Independent 12,059 6.8% 10,280 5.6% 22,339 6.2%
Supervision 11,817 6.6% 13,157 7.2% 24,974 6.9%
Limited Assistance 27,573 15.5% 27,142 14.8% 54,715 15.1%
Extensive Assistance 82,079 46.0% 95,166 51.7% 177,245 48.9%
Total Dependence 44,911 25.2% 38,265 20.8% 83,176 22.9%
Total 178,439 100% 184,010 100% 362,449 100%
Note:   (MDS) Minimum Data Set
            (ADL) Activities of Daily Living






The sample from 2011 contained observations from 723 facilities, and the sample 
from 2013 contained observations from 735 facilities. The facility sizes ranged from 18-
455 beds for 2011 and 12-455 for 2013. The average facility size for both years was 
approximately 140 beds. The frequencies per level of HRD for CNAs, LPNs, and RNs 
were similarly distributed between the two years. Detailed characteristics of the NH 
facilities from the two sample years are provided in Table 5. 
Table 5  Facility Characteristics 
 
 
In the 2013 sample, approximately 19% of the observations had a fall, and 9% 
had an infection. Approximately 68% of the sample received at least one psychotropic, 
2011 2013
Number of NHs 723 735
NH Size (Bed Count)
Mean 138.27 140.16
Standard Deviation 71.37 75.69
Mininum 18 12
Maximum 455 455
Frequency % Frequency %
CNA  Hours per Resident Day
Low 12,981 7% 14,659 8%
Medium 139,639 78% 145,857 79%
High 25,842 15% 23,540 13%
LPN  Hours per Resident Day
Low 20,124 11% 24,884 14%
Medium 137,828 77% 138,508 75%
High 20,510 12% 20,664 11%
RN  Hours per Resident Day
Low 25,726 14% 18,129 10%
Medium 131,028 74% 133,299 72%
High 21,708 12% 32,628 18%
OSCAR/CASPER Year
Note:  (OSCAR) Online Survey Certification and Reporting
          (CASPER) Certification and Survey Provider Enhanced Reporting
          (CNA) Certified Nursing Assistant       (NH) Nursing Home





with less than half a percent receiving all four types of psychotropic medications. The 
psychotropic with the greatest proportion of administration was antidepressant, at nearly 
56%. The detailed descriptive statistics of the outcome and predictor variables are 
presented in Table 6. 
Table 6  Descriptive Statistics for 2013 Outcome and Predictor Variables 
 
Variables Frequency % Mean Median Std Dev Variance
Outcome:
Falls Total 183,987 100.0% 0.1927 0 0.3944 0.1555
No 148,538 80.7%
Yes 35,449 19.3%




Antipsychotic Total 184,024 100.0% 0.2329 0 0.4227 0.1786
No 141,169 76.7%
Yes 42,855 23.3%
Antianxiety Total 184,022 100.0% 0.1984 0 0.3988 0.1590
No 147,510 80.2%
Yes 36,512 19.8%
Antidepressant Total 184,026 100.0% 0.5558 1 0.4969 0.2469
No 81,743 44.4%
Yes 102,283 55.6%
Hypnotic Total 184,022 100.0% 0.0458 0 0.2092 0.0437
No 175,585 95.4%
Yes 8,437 4.6%
Medications Total 184,056 100.0% 0.6837 1 0.4650 0.2163
(None or Any Number) None 58,222 31.6%
Any 125,834 68.4%
Multiple Medications Total 184,056 100.0% 1.0328 1 0.9010 0.8118










Bivariate Analysis were performed for the outcome variables with the predictors 
and covariates. T-tests were utilized for bed count, the single continuous variable, and 
chi-square tests were performed for the other categorical variables. All six of the 
psychotropic medication predictor variables and all covariates were found to be 




For the comparison of the psychotropic usage data between 2011 and 2013, chi-
square tests were employed. The chi-square tests utilized two dichotomized variables 
from combined data for 2011 and 2013. The first variable was defined for each of the 
four psychotropics (given/not given). The second variable was defined as the assessment 
year (2011/2013). 
Hypothesis 1 
Each of the four psychotropics were examined to determine if there were 
differences in medication usage across years. The results from the four chi-square tests all 
indicated that the administration of psychotropics were each different between the two 
years of assessment. 
Between the two years for all four psychotropics, the proportions of medications 
given or not given were similar, as was the direction of change for overall percentages. 
From 2011 to 2013, the percentages of psychotropics given per year all decreased, 





antipsychotic and hypnotic also decreased in actual frequency, from 47,107 to 42,855 and 
from 10,013 to 8,437, respectively. 
Antidepressant was the only psychotropic medication of the four for which the 
distributions revealed a higher proportion of those in receipt of the medication versus 
those who were not. The distributions for hypnotic were the lowest proportions out of the 
four psychotropic medications. Histograms for each psychotropic medication type 
compared individually between both years are available in Appendix C. The results from 
the chi-square tests are outlined in Table 7. 




Not given 130,520 73.48% 141,169 76.71% 271,689
Given 47,107 26.52% 42,855 23.29% 89,962
Total 177,627 100% 184,024 100% 361,651
Pearson chi2(1) = 505.3676
Antianxiety
Not given 141,818 79.83% 147,510 80.16% 289,328
Given 35,824 20.17% 36,512 19.84% 72,336
Total 177,642 100% 184,022 100% 361,664
Pearson chi2(1) = 5.9777
Antidepressant
Not given 77,300 43.51% 81,743 44.42% 159,043
Given 100,341 56.49% 102,283 55.58% 202,624
Total 177,641 100% 184,026 100% 361,667
Pearson chi2(1) = 30.0178
Hypnotic
Not given 167,644 94.36% 175,585 95.42% 343,229
Given 10,013 5.64% 8,437 4.58% 18,450
Total 177,657 100% 184,022 100% 361,679
Pearson chi2(1) = 206.3958
Note:  (Pearson chi2) Pearson's chi-squared          (Pr) P-value










For the year 2013, the mean number of days that medication was administered 
was relatively low when the medication variable was examined as the count of days 
administered in the past seven days. The mean number of days for antipsychotic was 1.6 
days. The mean number of days for antianxiety was 1.2 days. The mean number of days 
for antidepressant was 3.8 days. The mean number of days for hypnotic was 0.3 days. 
When the count data for the psychotropics in 2013 were examined, a pattern of 
distribution throughout the seven days was observed. Among those who received any of 
the psychotropic medications, the majority of them were administered the psychotropics 
for all seven days. The number of assessments indicating the receipt of medications from 
one to six days were very minimal as compared to all seven days. 
For those that received antipsychotic medication in 2013, 95% (40,747 out of 
42,855) of those had this medication administered for all seven days prior to the 
assessment. Similarly for antianxiety, 79% (29,006 out of 36,512) were administered for 
all seven days prior to the assessment. In addition, the proportions for antidepressant and 
hypnotic were 96% (98,494 out of 102,283) and 72% (6,103 out of 8,437) respectively. 
Due to this distribution of the count data, the 2013 psychotropic medication 
administration data were recoded as dichotomous variables for use in the data analyses 

















Generalized estimating equations with logistic regression were run for the data 
from 2013. There were six different models included in this set of analyses. The first set 
of three models used the medication administration variables (binary response, none or 
any, and combination count) individually, each with falls as the dependent variable. The 
second set of three models used the same medication administration variable individually, 





administration data in the newer format (“seven day count”) were not utilized in the 
analyses for Aim 2. 
 
Hypothesis 2 
Key results from the three models for psychotropics and falls are presented in 
Table 8. The full set of results from each of the three models are available in Appendix 
D, E, and F. 
Model 1 examined falls as the dependent variable. Medication administration for 
each of the four psychotropics was recoded as the “binary” variable (received/not 
received) for inclusion in the model as four individual predictor variables. For these four 
psychotropic types, the odds of having a fall were higher by 10-44% for NH residents 
that received the psychotropic versus those that did not receive one (antipsychotic – odds 
ratio (OR) 1.24 [95% CI 1.20-1.28]; antianxiety – OR 1.44 [95% CI 1.39-1.49]; 
antidepressant – OR 1.32 [95% CI 1.28-1.36]; hypnotic – OR 1.10 [95% CI 1.04-1.17]). 
Antianxiety medications had the highest OR at 1.44. 
The size of the facility had no effect on the odds of falling. High CNA staffing 
levels indicated a marginally higher odds of falling versus low CNA staffing (OR 1.09 
[95% CI 1.02-1.16]). High LPN staffing had a protective effect from falls versus low 
LPN staffing (OR 0.89 [95% CI 0.84-0.95]). Medium CNA, medium LPN, and both 
medium and high RN staffing levels were not significant. Females were less likely to fall 





Model 2 examined falls as the dependent variable and with medication 
administration as the “none or any” variant. For this psychotropic medication variable, 
the odds of having a fall was 56% higher for those receiving any medication versus those 
not receiving medication (OR 1.56 [95% CI 1.51-1.61]). 
Similar to Model 1, the size of the facility was not associated with falls. Also, 
high CNA staffing levels indicated a marginally higher odds of falling versus low CNA 
staffing (OR 1.09 [95% CI 1.02-1.17]). High LPN and RN staffing had protective effects 
from falls versus low staffing (OR 0.89 [95% CI 0.84-0.95] and OR 0.93 [95% CI 0.87-
0.99] respectively). Medium staffing levels for CNA, LPN, and RN were not significant. 
Also, females were less likely to fall, with OR 0.77 [95% CI 0.74-0.79]. 
Model 3 examined falls as the dependent variable and with medication 
administration as the “combination count” variant. Notably, this model produced the 
highest OR values than any of the other five models when examining psychotropic 
medication usage and risk for the particular negative outcome (either falls or infections). 
For each increasing level of medication count combinations, the odds of having a fall 
rose from 39% to 148% higher than those not receiving any psychotropic medications. 
The ORs per count level are as follows: any one psychotropic – OR 1.39 [95% CI 1.35-
1.44]; any two psychotropics – OR 1.79 [95% CI 1.72-1.87]; any three psychotropics – 
OR 2.24 [95% CI 2.12-2.37]; all four psychotropics – OR 2.48 [95% CI 2.08-2.95]. 
As with the previous two models, facility size was not associated with falls. High 
CNA staffing levels indicated a marginally higher odds of falling versus low CNA 





protective from falls versus low LPN staffing (OR 0.89 [95% CI 0.84-0.95]. Medium 
CNA, medium LPN, and both medium and high RN staffing levels were not significant. 
Again, females were less likely to fall, with OR 0.76 [95% CI 0.73-0.78]. 
For all three models, increase in age group and diagnoses of either Alzheimer’s 
disease or non-Alzheimer’s dementia were all associated with an increased odds of 





Table 8  Generalized Estimating Equations with Logistic Regression – Falls 
Odds Ratio
Antipsychotic No (reference)
Yes 1.24 *** [ 1.20 1.28 ]
Antianxiety No (reference)
Yes 1.44 *** [ 1.39 1.49 ]
Antidepressant No (reference)
Yes 1.32 *** [ 1.28 1.36 ]
Hypnotic No (reference)
Yes 1.10 ** [ 1.04 1.17 ] Odds Ratio
No (reference)
Yes 1.56 *** [ 1.51 1.61 ] Odds Ratio
None (reference)
One 1.39 *** [ 1.35 1.44 ]
Two 1.79 *** [ 1.72 1.87 ]
Three 2.24 *** [ 2.12 2.37 ]
Four 2.48 *** [ 2.08 2.95 ]
Facility Size Bed Count 1.00 [ 1.00 1.00 ] 1.00 [ 1.00 1.00 ] 1.00 [ 1.00 1.00 ]
Certified Nursing Assistant Low (reference) (reference) (reference)
Medium 1.02 [ 0.96 1.07 ] 1.02 [ 0.96 1.07 ] 1.02 [ 0.96 1.07 ]
High 1.09 * [ 1.02 1.16 ] 1.09 * [ 1.02 1.17 ] 1.09 * [ 1.02 1.16 ]
Licensed Practical Nurse Low (reference) (reference) (reference)
Medium 0.97 [ 0.93 1.02 ] 0.98 [ 0.93 1.02 ] 0.98 [ 0.93 1.02 ]
High 0.89 *** [ 0.84 0.95 ] 0.89 ** [ 0.84 0.95 ] 0.89 *** [ 0.84 0.95 ]
Registered Nurse Low (reference) (reference) (reference)
Medium 1.01 [ 0.96 1.07 ] 1.00 [ 0.95 1.06 ] 1.01 [ 0.96 1.06 ]
High 0.94 [ 0.88 1.01 ] 0.93 * [ 0.87 0.99 ] 0.94 [ 0.88 1.01 ]
Age 65-74 (reference) (reference) (reference)
75-84 1.22 *** [ 1.17 1.28 ] 1.19 *** [ 1.14 1.25 ] 1.23 *** [ 1.17 1.28 ]
85-94 1.35 *** [ 1.29 1.42 ] 1.29 *** [ 1.23 1.35 ] 1.36 *** [ 1.30 1.42 ]
95 & older 1.53 *** [ 1.44 1.63 ] 1.44 *** [ 1.36 1.54 ] 1.54 *** [ 1.45 1.64 ]
Gender Male (reference) (reference) (reference)
Female 0.75 *** [ 0.73 0.78 ] 0.77 *** [ 0.74 0.79 ] 0.76 *** [ 0.73 0.78 ]
Race White (reference) (reference) (reference)
Black 0.83 *** [ 0.78 0.87 ] 0.79 *** [ 0.75 0.84 ] 0.82 *** [ 0.78 0.87 ]
Hispanic 0.90 ** [ 0.84 0.97 ] 0.89 ** [ 0.82 0.96 ] 0.90 ** [ 0.83 0.97 ]
Asian 0.90 [ 0.78 1.03 ] 0.88 [ 0.77 1.01 ] 0.90 [ 0.78 1.03 ]
American Indian/Alaskan Native 1.07 [ 0.83 1.40 ] 1.06 [ 0.81 1.37 ] 1.07 [ 0.82 1.39 ]
Native Hawaiian/Pacific Islander 0.83 [ 0.49 1.40 ] 0.82 [ 0.49 1.38 ] 0.82 [ 0.48 1.38 ]
MultiRace 0.97 [ 0.74 1.28 ] 0.96 [ 0.73 1.26 ] 0.97 [ 0.74 1.28 ]
Unknown 0.92 [ 0.83 1.03 ] 0.91 [ 0.82 1.02 ] 0.92 [ 0.83 1.03 ]
Alzheimer's Disease No (reference) (reference) (reference)
Yes 1.17 *** [ 1.13 1.21 ] 1.18 *** [ 1.14 1.22 ] 1.17 *** [ 1.12 1.21 ]
Non-Alzheimer's Dementia No (reference) (reference) (reference)
Yes 1.23 *** [ 1.19 1.27 ] 1.24 *** [ 1.21 1.28 ] 1.22 *** [ 1.19 1.26 ]
Note:  (CI) Confidence Interval      *Denotes p-value < 0.05     **Denotes p-value < 0.01     ***Denotes p-value < 0.001
95% CI
Model 1 Model 2 Model 3













Key results from the three models for psychotropics and infections are presented 
in Table 9. The full set of results data from each of the three models are available in 
Appendix G, H, and I. 
Model 1 examined infections as the dependent variable. Medication 
administration for each of the four psychotropics was recoded as the “binary” variable 
(received/not received) for inclusion in the model as four individual predictor variables. 
For antipsychotics, the odds of having an infection were slightly less for those receiving 
medication than for those not receiving medication, however, it was not significant. 
Antipsychotic was the only one of the four psychotropics not associated with an 
increased odds of infection. For each of the other three psychotropic types, the odds of 
having an infection were approximately 7-22% higher for those receiving the medication 
than those not receiving the medication (antianxiety – OR 1.07 [95% CI 1.03-1.12]; 
antidepressant – OR 1.08 [95% CI 1.04-1.13]; hypnotic – OR 1.22 [95% CI 1.13-1.32]). 
Facility size and gender were not associated with infections, and CNA staffing 
levels (medium and high) were not significant. Medium and high LPN staffing levels had 
an OR values of 1.17 [95% CI 1.09-1.25] and 1.18 [95% CI 1.08-1.28] respectively, 
indicating increased odds of infection as LPN staffing levels increased. In contrast, 
medium and high RN staffing levels had protective effects, (OR 0.86 [95% CI 0.81-0.92] 
and OR 0.89 [95% CI 0.82-0.97] respectively). 
Model 2 examined infections as the dependent variable and with medication 





higher for those receiving any medication versus those not receiving medication (OR 
1.12 [95% CI 1.07-1.16]). 
Similar to the previous model, facility size and gender were not substantively 
associated with having any infection, and both medium and high CNA staffing levels 
were not significant.  Also akin to Model 1, both medium and high LPN staffing levels 
had OR values to indicate increased risk of infection as staffing levels increased, and both 
RN staffing levels had protective ORs versus low staffing. 
Model 3 examined infections as the dependent variable and with medication 
administration as the “combination count” variant. Overall, the odds of having an 
infection as the combination of medications increased were 11-25% higher than those not 
receiving any psychotropic medications. The odds per level of medication count are as 
follows: any one psychotropic – OR 1.11 [95% CI 1.06-1.16]; any two psychotropics – 
OR 1.12 [95% CI 1.06-1.18]; any three psychotropics – OR 1.18 [95% CI 1.09-1.28]; all 
four psychotropics – OR 1.25 [95% CI 0.98-1.60]. Receiving all four psychotropic types 
was associated with an increased odds of infection but was not significant, as indicated 
by the CI. The pattern for OR values for facility size, CNA, LPN, & RN staffing levels, 
and gender were identical to the prior two models. 
For the regression models four through six, higher age group, and diagnoses of 
either Alzheimer’s disease or non-Alzheimer’s dementia were all associated with 
decreased odds of infection. For the age group categories, the ORs were only significant 





Alzheimer’s dementia were significant at p-value < 0.001. The race categories for each of 





Table 9  Generalized Estimating Equations with Logistic Regression – Infections 
Odds Ratio
Antipsychotic No (reference)
Yes 0.96 [ 0.91 1.00 ]
Antianxiety No (reference)
Yes 1.07 ** [ 1.03 1.12 ]
Antidepressant No (reference)
Yes 1.08 *** [ 1.04 1.13 ]
Hypnotic No (reference)
Yes 1.22 *** [ 1.13 1.32 ] Odds Ratio
No (reference)
Yes 1.12 *** [ 1.07 1.16 ] Odds Ratio
None (reference)
One 1.11 *** [ 1.06 1.16 ]
Two 1.12 *** [ 1.06 1.18 ]
Three 1.18 *** [ 1.09 1.28 ]
Four 1.25 [ 0.98 1.60 ]
Facility Size Bed Count 1.00 *** [ 1.00 1.00 ] 1.00 *** [ 1.00 1.00 ] 1.00 *** [ 1.00 1.00 ]
Certified Nursing Assistant Low (reference) (reference) (reference)
Medium 0.96 [ 0.90 1.03 ] 0.97 [ 0.90 1.04 ] 0.97 [ 0.90 1.04 ]
High 1.04 [ 0.96 1.14 ] 1.05 [ 0.96 1.14 ] 1.05 [ 0.96 1.14 ]
Licensed Practical Nurse Low (reference) (reference) (reference)
Medium 1.17 *** [ 1.09 1.25 ] 1.17 *** [ 1.09 1.25 ] 1.17 *** [ 1.09 1.25 ]
High 1.18 *** [ 1.08 1.28 ] 1.18 *** [ 1.08 1.29 ] 1.18 *** [ 1.08 1.29 ]
Registered Nurse Low (reference) (reference) (reference)
Medium 0.86 *** [ 0.81 0.92 ] 0.86 *** [ 0.81 0.92 ] 0.86 *** [ 0.81 0.92 ]
High 0.89 ** [ 0.82 0.97 ] 0.89 ** [ 0.82 0.97 ] 0.89 ** [ 0.82 0.97 ]
Age 65-74 (reference) (reference) (reference)
75-84 1.01 [ 0.95 1.07 ] 1.01 [ 0.96 1.07 ] 1.02 [ 0.96 1.08 ]
85-94 0.99 [ 0.93 1.05 ] 0.99 [ 0.93 1.05 ] 0.99 [ 0.94 1.06 ]
95 & older 0.81 *** [ 0.75 0.89 ] 0.82 *** [ 0.75 0.89 ] 0.82 *** [ 0.75 0.89 ]
Gender Male (reference) (reference) (reference)
Female 0.98 [ 0.94 1.03 ] 0.98 [ 0.94 1.03 ] 0.98 [ 0.94 1.03 ]
Race White (reference) (reference) (reference)
Black 0.76 *** [ 0.71 0.82 ] 0.75 *** [ 0.70 0.81 ] 0.76 *** [ 0.70 0.81 ]
Hispanic 0.85 ** [ 0.77 0.94 ] 0.85 ** [ 0.77 0.93 ] 0.85 ** [ 0.77 0.93 ]
Asian 0.89 [ 0.74 1.07 ] 0.89 [ 0.74 1.08 ] 0.89 [ 0.74 1.08 ]
American Indian/Alaskan Native 1.35 [ 0.96 1.88 ] 1.34 [ 0.96 1.88 ] 1.34 [ 0.96 1.88 ]
Native Hawaiian/Pacific Islander 1.20 [ 0.67 2.15 ] 1.21 [ 0.68 2.17 ] 1.21 [ 0.68 2.16 ]
MultiRace 1.06 [ 0.75 1.52 ] 1.06 [ 0.74 1.52 ] 1.06 [ 0.74 1.52 ]
Unknown 0.88 [ 0.76 1.02 ] 0.88 [ 0.76 1.02 ] 0.89 [ 0.76 1.03 ]
Alzheimer's Disease No (reference) (reference) (reference)
Yes 0.80 *** [ 0.76 0.84 ] 0.79 *** [ 0.75 0.83 ] 0.79 *** [ 0.75 0.83 ]
Non-Alzheimer's Dementia No (reference) (reference) (reference)
Yes 0.91 *** [ 0.87 0.94 ] 0.90 *** [ 0.86 0.93 ] 0.89 *** [ 0.86 0.93 ]
95% CI
Covariates
Note:  (CI) Confidence Interval      *Denotes p-value < 0.05     **Denotes p-value < 0.01     ***Denotes p-value < 0.001
Multiple Medications (Any Combination)
Model 1 Model 2 Model 3
95% CI
95% CI








Chapter 5 – Discussion 
This chapter provides a discussion of the results from the dissertation. Next, the 
strengths and limitations of the study are presented. Finally, the implications for clinical 
practice, policy, and future research are offered. 
 
Discussion of the Findings 
This dissertation provides the first study that utilized national NH data to examine 
the associations of psychotropic medications with both falls and infections. It is also the 
first study to include facility characteristics in those analyses. This novel approach is 
significant for examining the influence of nursing care in NHs and its effect on nursing 
sensitive outcomes (falls, infections). Both unique aspects contribute to the gaps in 
knowledge found in previous research literature. 
In addressing the analysis for the first aim, the number psychotropics given in 
2011 and 2013 had only minor but significant differences (0.3 to 3.23 percentage points). 
The statistical significance of the difference of proportions between 2011 and 2013 may 
be attributed to the very large sample size (~179,000 and ~185,000 respectively). 
An unexpected finding was the proportional decline in usage across all four 
psychotropics from 2011 to 2013. The sample sizes were larger in 2013 than 2011, which 
concurs with researchers that report growth in the NH population (Vincent & Velkoff, 





actually declined in usage numbers. This may be attributed to a higher level of awareness 
and/or scrutiny, especially for antipsychotics (Mitka, 2012). 
Another finding of note was the difference of proportions between received/not 
received among antidepressants versus the other three psychotropics. Antidepressants 
were the only psychotropic that had a higher proportion of those in receipt of that class of 
psychotropic than those not having received it (~56% for both years). The other three 
psychotropics had comparatively much less for received versus not received. This may be 
due to the very high prevalence of depressive symptoms among NH residents. Diagnostic 
depression criteria, such as mood disorders and depressive symptoms, are reported as 
being common and represent approximately 20% of NH residents (Shah, Schoenbachler, 
Streim, & Meeks, 2012). Researchers have indicated that approximately 44% of NH 
residents were assessed with significant depressive symptoms, and approximately 14% of 
NH residents were assessed with probable/definite major depression (Teresi, Abrams, 
Holmes, Ramirez, & Eimicke, 2001). Estimates from other researchers indicate a 
prevalence of up to 50% of NH residents with depressive symptoms and up to 26% of 
those with Major Depression Disorder (Boyce et al., 2012). For depressed NH residents, 
approximately 74% are treated with antidepressants alone (Boyce et al., 2012; Levin et 
al., 2007). This provides validity to the findings that antidepressants were utilized among 
approximately 56% of the resident observations.  
All four psychotropics were found to be associated with a higher odds of resident 
falls than those not in receipt of those medications. These findings are congruent with 





receiving any combination of three or all four were associated with a 2¼ to 2½ times 
increased odds of having a fall. This finding is important for health care providers in 
planning treatment for NH residents by identifying the increased risk with multiple 
psychotropics. 
An additional covariate in all of the models was Alzheimer’s disease and non-
Alzheimer’s dementia; both were both associated with an increased odds of having a fall 
(by approximately 17-24%). This finding is similar to other studies wherein researchers 
posit that NH residents with a form of dementia and receiving psychotropics were more 
likely to have adverse effects, including falls (Galik & Resnick, 2013). 
This is the first study to find antipsychotic, antianxiety, antidepressant, and 
hypnotic medication usage to be associated with NH residents having an infection. These 
findings do correspond with studies that had utilized samples from among the overall 
elderly population in which usage of psychotropics was associate with increased risk for 
infections, including community-acquired pneumonia and Clostridium Difficile (Gau et 
al., 2010; C. Huang et al., 2014; Knol et al., 2008; Rogers et al., 2013; Trifiro et al., 
2010). However, antipsychotics was not associated with an increased risk for infections. 
The association between antipsychotics and infections has been inconsistent in previous 
literature with some researchers finding a significant association. (Gau et al., 2010; Knol 
et al., 2008; Trifiro et al., 2010).  
Compared to that of falls, the OR for hypnotics and infection was slightly higher, 
by approximately 12 percentage points (10% versus 22%). Also, the OR for hypnotics 





hypnotics and falls was the lowest of the four. The results indicate that hypnotic 
medications may be more influential in risk for infections, and this corresponds to 
findings from other research (C. Huang et al., 2014). 
 The staffing variables were operationalized as low, medium, and high HRD 
staffing levels for CNAs, LPNs, and RNs. Inclusion of these variables is noteworthy in 
the potential to provide insight into staffing levels as they apply to NH care. Minimum 
staffing levels in NHs were mandated by federal legislation in 1987 and have not changed 
since then; however, these staffing levels are inadequately low, especially when 
considering the acuity levels of NH residents (Harrington, Schnelle, McGregor, & 
Simmons, 2016). NH staffing levels have been linked with overall quality of care (Collier 
& Harrington, 2008; Harrington et al., 2016; Needleman et al., 2001). Higher staffing 
levels have also been associated with increased individual attention to NH residents that 
improve quality of life and experience of care (Li et al., 2015).  
 CNA staffing was not associated with falls or infections. Results from previous 
studies have indicated similar results for CNAs, but the researchers attributed that to low 
CNA staffing levels for the facilities in the studies (Collier & Harrington, 2008).  
For falls, high staffing levels for both RNs and LPNs were associated with slightly 
protective with less odds of having a fall, by approximately 6-11%. These staffing 
variable results show the positive effect that increased staffing may have on preventing 
falls among NH residents, which was validated by similar results in numerous studies 
(Collier & Harrington, 2008; Harrington et al., 2016; Hongsoo Kim, Harrington, & 





with increased odds for infection (by approximately 17-18%). Whereas the increasing RN 
staffing levels was associated with a decreased odds for infection (by approximately 11-
14%). This would appear to indicate that the increase in staffing for LPNs within a 
facility were associated with higher odds of having an infection but that an increase in 
staffing for RNs were protective from infection. It is unclear as to the counterintuitive 
results for LPN and RN HRDs for infection, but it warrants further research.  
 The other two facility level variables (size, location) had similar results across all 
models and were not associated with having any effect on the odds of having a fall or 
infection. The only difference was that the ORs for facility size were not significant for 
falls, but for infection the ORs for facility size were significant with p-values < 0.001.  
 
Strengths and Limitations 
The strengths of this dissertation are in the use of national NH data and the results 
are generalizable to NHs of different sizes and within different settings. Also, this study 
examined all four types of psychotropic medications, which provided more opportunity to 
gain information about the effects of psychotropic usage in NHs. Much of the prior 
research used data greater than 10 years ago, and this study supports the previous 
published research. 
Nonetheless, there are several limitations to address. The first limitation is in the 
MDS data and the process whereby it is collected. The data are entered by the clinical 
staff administering the assessment, and the potential for error or misinformation is 





and confirmed across those sources. Also, the MDS does not allow for the collection of 
more in-depth medication data, such as drug name, dosage, or frequency. Also, within a 
specific type of psychotropic, there is no opportunity to enter if the NH resident is 
receiving multiple different drugs of the same type (e.g. two different antidepressant 
drugs). 
In addition, the falls data are collected on a look-back period based on the time 
period between the current assessment and the previous assessment, which may be up to 
90 days. The infection variables have a look-back period of seven days, except for 
urinary tract infections which has a look-back period of 30 days. Also, the primary 
predictor variables (psychotropic medications) have a look-back period of only seven 
days. This variation in look-back periods can potentially associate a fall or infection that 
occurred prior to the administration of a psychotropic and temporality cannot be assured. 
Using medication chart or prescription data would address this limitation. However, these 
data were not available. . 
Another limitation may be the types of infections that were included in this study 
(multidrug-resistant organism, pneumonia, septicemia, urinary tract infection, and wound 
infection other than foot). Inclusion of other types of infection may have provided 
additional insight to the analytic results. Despite the various limitations, this dissertation 
provided significant information regarding the use of psychotropic medications and the 





Implications for Clinical Practice 
According to experts, the staffing HRD guidelines indicate minimums of 2.7 for 
CNAs, 0.7 for LPNs, and 1.15 for RNs (Harrington et al., 2000). However, these 
recommendations are over 15 years old, and they may not accurately reflect the acuity 
level and needs of current NH residents. In addition, federal guidelines do not provide the 
optimal guidelines for NH staffing, with recommendations that were established about 29 
years ago.  
The facilities with the best CNA staffing levels (averaging 3.43 HRD) were found 
to perform better in over 80% of the patient care processes (Collier & Harrington, 2008). 
Staffing levels for RNs would need to be at 1.8 to 3.3 HRD for facilities to be considered 
upper tier in quality (N. Zhang, Unruh, Liu, & Wan, 2006). High staffing levels were 
found to be linked with better quality of care and fewer deficiencies, which are both 
associated with improved resident outcomes (Collier & Harrington, 2008; Wan, Zhang, & 
Unruh, 2006). Therefore, facilities need to evaluate nursing practice guidelines, so that 
the time of patient interaction between nursing staff and resident is optimized for 
improved quality and outcomes. 
In addition, providers can assess their treatment policies to ensure only necessary 
medication usage and monitor NH resident status and outcomes accordingly. The 
providers may adjust the dosing levels when prescribing psychotropics to minimize 
adverse effects. Also, other treatment options can be explored as supplemental to or in 






Implications for Policy 
From the federal policy imposed in 1987 (OBRA) to research studies being 
conducted currently, the evidence of adverse outcomes associated with usage of 
psychotropics is apparent. The results from this study concur with such inferences. 
Although there are many legitimate circumstances that warrant the use of a particular 
psychotropic medication, NH policies on the usage of psychotropics may need to be 
reviewed and potentially revised to avoid overuse and/or misuse of these types of drugs.  
Federal guidelines and initiatives to decrease unnecessary psychotropic 
medication usage may have helped, as indicated in the proportional and usage counts 
presented in the results of the first aim in this dissertation. Federal policy efforts thus far 
may be insufficient as NHs face a rapidly growing senior population, where sufficient 
NH staffing levels and more appropriate psychotropic medication usage are not mandated 
by legislative policy. 
 
Implications for Future Research 
Although this study utilized very recent data and provided results that indicated an 
increased risk for falls and infections from psychotropic medication usage, much more 
research is necessary to hone in on the particulars by which this study was constrained. 
Inclusion of the specifics relating to drug name, dosage, and frequency and the 
multiplicity within and across psychotropic types would provide deeper insight as to their 





conjunction with complete data on falls or infections would allow for more accurate 
calculation of the risk associations between the psychotropics and outcomes. Future 
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Covariates A B C D E F G H I J K L M N
Age X X X X X X X X X X X X X X
Gender X X X X X X X X X X X X
Race/Ethnicity X X X X
Psychotropic Medication X X X X X X X X X X X X X X
Other Medications X X X X X
Total Number of Drugs X X X X X
Polypharmacy X
BMI X X X
Dementia X X X X





Number of Diagnoses X
Urinary Incontinence X X X
Parkinson's Disease X X
Arthitis & other joint diseases X X
Stroke X X X




Cardiovascular Disease X X
Anemia X






Use of Assistive Device X
Upper Extremity Weakness X
Lower Extremity Weakness X
Vision X X X
Hearing X
>=20 mmHg postural drop in systolic pressure X
Walking Ability X
Falls History X X X X X X X X
Falls During 1 year Follow-up X
Ambulatory X X






A B C D E F G H I J K L M N
Wheelchair-bound X
Chairbount or bedbound X
No Mobility Device used to Ambulate X
Fell during Oct. 1990 X
Emergency Room Visit X
Length of Stay in NH X X X X X
Time Since Admission X
Admitted in Previous 90 Days X
Admission to NH X
Mental Capacity X
Treatment Program X
Dependency Status Level X
Pain Level X
Have Private Insurance X
Restraints Used X X
Memory Problems X
Activity Level X
Functional Status X X
Impaired ADLs X X X X X
ADLs Hierarchy Scale X
Decision-making Ability for ADLs X
Cognitive Impairment X X X
Cognitive Performance Scale X
Rug III Categorization X
Case Mix Index Mean X
Burden of Illness Mean X
Personal Severity Index X
Resident Classification Scale X
Implicit Illness Severity Scale X
Mini-mental Exam X
Static Balance Score / Balance Test X X X
Table Key for the 14 Studies
Agashivala & Wu A
Thapa et al. (1995) B
Sterke et al. C
Hien et al. D
Nygaard E
Neutel et al. F
Mustard & Mayer G
Echt et al. H
Arfken et al. I
Berry et al. J
Thapa et al. (1998) K
Ruthazer & Lipsitz L
Ray et al. M







N0410A Medications Received: Hours per Resident Day:
Antipsychotic no yes Total CNA no yes Total
no 115,855 25,263 141,118 Low 11,903 2,752 14,655
yes 32,663 10,183 42,846 Med 117,927 27,867 145,794
High 18,708 4,830 23,538
Total 148,518 35,446 183,964
Total 148,538 35,449 183,987
Pearson chi2(1) = 726.6700 Pr = 0.000
Pearson chi2(2) =  28.2010 Pr = 0.000
N0410B Medications Received:
Antianxiety no yes Total Hours per Resident Day:
no 121,300 26,161 147,461 LPN no yes Total
yes 27,217 9,284 36,501 Low 19,638 5,245 24,883
Med 111,807 26,635 138,442
Total 148,517 35,445 183,962 High 17,093 3,569 20,662
Total 148,538 35,449 183,987
Pearson chi2(1) =  1.1e+03 Pr = 0.000
Pearson chi2(2) = 105.3734 Pr = 0.000
N0410C Medications Received:
Antidepressant no yes Total Hours per Resident Day:
no 68,775 12,940 81,715 RN no yes Total
yes 79,745 22,506 102,251 Low 14,554 3,573 18,127
Med 107,467 25,768 133,235
Total 148,520 35,446 183,966 High 26,517 6,108 32,625
Total 148,538 35,449 183,987
Pearson chi2(1) =  1.1e+03 Pr = 0.000
Pearson chi2(2) =   8.9899 Pr = 0.011
N0410D Medications Received:
Hypnotic no yes Total Age
no 141,863 33,665 175,528 Year Categories no yes Total
yes 6,653 1,781 8,434 65-74 27,118 5,200 32,318
75-84 47,414 11,138 58,552
Total 148,516 35,446 183,962 85-94 60,777 15,528 76,305
95&older 13,229 3,583 16,812
Pearson chi2(1) =  19.4227 Pr = 0.000 Total 148,538 35,449 183,987
Psychotropic Medication Received: Pearson chi2(3) = 314.6785 Pr = 0.000
Binary - None or Any no yes Total
no 50,076 8,114 58,190 Gender
yes 98,462 27,335 125,797 no yes Total
male 39,326 10,714 50,040
Total 148,538 35,449 183,987 female 109,212 24,735 133,947
Total 148,538 35,449 183,987
Pearson chi2(1) =  1.6e+03 Pr = 0.000
Pearson chi2(1) = 203.0730 Pr = 0.000
Psychotropic Medication Received:
Multiple Medications no yes Total Race of Resident
0 50,076 8,114 58,190 no yes Total
1 59,807 14,530 74,337 White 116,425 29,717 146,142
2 30,057 9,415 39,472 Black 18,304 3,127 21,431
3 8,035 3,166 11,201 Hispanic 8,076 1,480 9,556
4 563 224 787 Asian 2,449 413 2,862
AmericanIndian/Alaska 393 110 503
Total 148,538 35,449 183,987 NativeHawaiian/Pacifi 151 22 173
MultiRace 426 90 516
Pearson chi2(4) =  2.2e+03 Pr = 0.000 Unknown 2,314 490 2,804
Total 148,538 35,449 183,987


















G0110A ADL Assistance: G0110I ADL Assistance:
Bed Mobility no yes Total Toileting no yes Total
0 18,130 4,368 22,498 0 11,531 2,216 13,747
1 12,371 2,939 15,310 1 10,408 2,131 12,539
2 16,228 5,344 21,572 2 14,990 4,701 19,691
3 79,761 20,723 100,484 3 75,852 21,993 97,845
4 22,038 2,073 24,111 4 35,750 4,406 40,156
Total 148,528 35,447 183,975 Total 148,531 35,447 183,978
Pearson chi2(4) =  2.3e+03 Pr = 0.000 Pearson chi2(4) =  2.8e+03 Pr = 0.000
G0110B ADL Assistance: G0110J ADL Assistance:
Transfer no yes Total Personal Hygiene no yes Total
0 14,879 3,133 18,012 0 8,611 1,669 10,280
1 13,735 3,105 16,840 1 10,875 2,269 13,144
2 17,427 5,952 23,379 2 21,145 5,988 27,133
3 68,326 20,032 88,358 3 74,427 20,720 95,147
4 34,164 3,224 37,388 4 33,463 4,800 38,263
Total 148,531 35,446 183,977 Total 148,521 35,446 183,967
Pearson chi2(4) =  4.0e+03 Pr = 0.000 Pearson chi2(4) =  1.7e+03 Pr = 0.000
G0110E ADL Assistance: B0700 Makes Self Understood
Locomotion on Unit no yes Total no yes Total
0 22,489 5,186 27,675 understood 81,377 18,441 99,818
1 23,653 6,460 30,113 usually understood 32,457 9,508 41,965
2 19,256 6,467 25,723 sometimes understood 19,632 5,327 24,959
3 39,276 11,932 51,208 rarely/never understood 14,795 2,158 16,953
4 43,804 5,388 49,192 Total 148,261 35,434 183,695
Total 148,478 35,433 183,911
Pearson chi2(3) = 884.4667 Pr = 0.000
Pearson chi2(4) =  3.4e+03 Pr = 0.000
I4200 Active Diagnoses:
G0110G ADL Assistance: Alzheimers no yes Total
Dressing no yes Total no 120,471 27,726 148,197
0 7,913 1,497 9,410 yes 28,035 7,716 35,751
1 8,866 1,820 10,686 Total 148,506 35,442 183,948
2 18,856 5,489 24,345
3 84,093 23,043 107,136 Pearson chi2(1) = 152.9161 Pr = 0.000
4 28,776 3,591 32,367
Total 148,504 35,440 183,944 I4800 Active Diagnoses:
Dementia no yes Total
Pearson chi2(4) =  2.0e+03 Pr = 0.000 no 73,865 15,217 89,082
yes 74,623 20,223 94,846
G0110H ADL Assistance: Total 148,488 35,440 183,928
Eating no yes Total
0 39,225 9,531 48,756 Pearson chi2(1) = 530.8682 Pr = 0.000
1 53,060 14,106 67,166
2 15,731 4,448 20,179
3 22,485 5,677 28,162
4 18,028 1,686 19,714
Total 148,529 35,448 183,977


















Alabama 1,480 335 1,815
Alaska 213 32 245
Arizona 849 214 1,063
Arkansas 1,944 534 2,478
California 11,003 1,703 12,706
Colorado 1,831 599 2,430
Connecticut 2,677 619 3,296
Delaware 786 210 996
District of Columbia 1,202 165 1,367
Florida 9,022 1,890 10,912
Georgia 5,566 1,597 7,163
Hawaii 109 34 143
Idaho 597 169 766
Ill inois 6,509 1,521 8,030
Indiana 4,845 1,186 6,031
Iowa 2,477 717 3,194
Kansas 2,555 819 3,374
Kentucky 3,842 1,041 4,883
Louisiana 2,834 780 3,614
Maine 656 167 823
Maryland 3,551 819 4,370
Massachusetts 6,002 1,190 7,192
Michigan 2,302 565 2,867
Minnesota 1,498 541 2,039
Mississippi 1,456 233 1,689
Missouri 2,614 939 3,553
Montana 329 104 433
Nebraska 1,337 496 1,833
New Hampshire 1,053 339 1,392
New Jersey 4,394 769 5,163
New Mexico 300 74 374
New York 14,338 2,481 16,819
North Carolina 2,941 703 3,644
North Dakota 943 373 1,316
Ohio 8,364 2,087 10,451
Oklahoma 1,789 514 2,303
Oregon 612 165 777
Pennsylvania 8,516 2,188 10,704
Rhode Island 516 122 638
South Carolina 1,914 449 2,363
South Dakota 629 239 868
Tennessee 3,433 779 4,212
Texas 11,675 2,742 14,417
Utah 467 166 633
Virginia 1,112 331 1,443
Washington 1,394 355 1,749
West Virginia 467 199 666
Wisconsin 3,232 1,000 4,232
Wyoming 363 155 518
Total 148,538 35,449 183,987







N0410A Medications Received: Hours per Resident Day:
Antipsychotic no yes Total CNA no yes Total
no 128,298 12,871 141,169 Low 13,273 1,386 14,659
yes 39,176 3,679 42,855 Med 132,887 12,970 145,857
High 21,337 2,203 23,540
Total 167,474 16,550 184,024
Total 167,497 16,559 184,056
Pearson chi2(1) =  11.3972 Pr = 0.001
Pearson chi2(2) =   9.4669 Pr = 0.009
N0410B Medications Received:
Antianxiety no yes Total Hours per Resident Day:
no 134,590 12,920 147,510 LPN no yes Total
yes 32,882 3,630 36,512 Low 22,951 1,933 24,884
Med 125,869 12,639 138,508
Total 167,472 16,550 184,022 High 18,677 1,987 20,664
Pearson chi2(1) =  50.0621 Pr = 0.000 Total 167,497 16,559 184,056
N0410C Medications Received: Pearson chi2(2) =  58.3434 Pr = 0.000
Antidepressant no yes Total
no 75,091 6,652 81,743 Hours per Resident Day:
yes 92,385 9,898 102,283 RN no yes Total
Low 16,274 1,855 18,129
Total 167,476 16,550 184,026 Med 121,494 11,805 133,299
High 29,729 2,899 32,628
Pearson chi2(1) = 131.5437 Pr = 0.000
Total 167,497 16,559 184,056
N0410D Medications Received:
Hypnotic no yes Total Pearson chi2(2) =  37.5203 Pr = 0.000
no 160,005 15,580 175,585
yes 7,467 970 8,437 Age
Year Categories no yes Total
Total 167,472 16,550 184,022 65-74 29,438 2,890 32,328
75-84 53,199 5,381 58,580
Pearson chi2(1) =  67.7112 Pr = 0.000 85-94 69,370 6,960 76,330
95&older 15,490 1,328 16,818
Psychotropic Medication Received:
Binary - None or Any no yes Total Total 167,497 16,559 184,056
no 53,577 4,645 58,222
yes 113,920 11,914 125,834 Pearson chi2(3) =  28.9371 Pr = 0.000
Total 167,497 16,559 184,056 Gender
no yes Total
Pearson chi2(1) = 107.9281 Pr = 0.000 male 45,651 4,412 50,063
female 121,846 12,147 133,993
Psychotropic Medication Received:
Multiple Medications no yes Total Total 167,497 16,559 184,056
0 53,577 4,645 58,222
1 67,399 6,962 74,361 Pearson chi2(1) =   2.8382 Pr = 0.092
2 35,747 3,734 39,481
3 10,079 1,125 11,204 Race of Resident
4 695 93 788 no yes Total
White 132,581 13,617 146,198
Total 167,497 16,559 184,056 Black 19,814 1,617 21,431
Hispanic 8,789 779 9,568
Pearson chi2(4) = 118.6826 Pr = 0.000 Asian 2,668 194 2,862
AmericanIndian/Alaska 452 52 504
NativeHawaiian/Pacifi 152 21 173
MultiRace 470 46 516
Unknown 2,571 233 2,804
Total 167,497 16,559 184,056


















G0110A ADL Assistance: G0110I ADL Assistance:
Bed Mobility no yes Total Toileting no yes Total
0 21,303 1,197 22,500 0 13,144 605 13,749
1 14,511 815 15,326 1 11,913 641 12,554
2 19,799 1,781 21,580 2 18,214 1,487 19,701
3 90,069 10,445 100,514 3 87,940 9,932 97,872
4 21,802 2,321 24,123 4 36,277 3,893 40,170
Total 167,484 16,559 184,043 Total 167,488 16,558 184,046
Pearson chi2(4) = 889.7510 Pr = 0.000 Pearson chi2(4) = 819.5266 Pr = 0.000
G0110B ADL Assistance: G0110J ADL Assistance:
Transfer no yes Total Personal Hygiene no yes Total
0 17,153 861 18,014 0 9,721 559 10,280
1 15,988 868 16,856 1 12,406 751 13,157
2 21,444 1,945 23,389 2 24,964 2,178 27,142
3 79,359 9,027 88,386 3 85,652 9,514 95,166
4 33,542 3,858 37,400 4 34,715 3,550 38,265
Total 167,486 16,559 184,045 Total 167,458 16,552 184,010
Pearson chi2(4) = 948.3946 Pr = 0.000 Pearson chi2(4) = 484.3055 Pr = 0.000
G0110E ADL Assistance: B0700 Makes Self Understood
Locomotion on Unit no yes Total no yes Total
0 25,992 1,684 27,676 understood 90,611 9,249 99,860
1 28,143 1,988 30,131 usually understood 37,949 4,022 41,971
2 23,399 2,331 25,730 sometimes understood 22,936 2,026 24,962
3 45,744 5,478 51,222 rarely/never understood 15,748 1,208 16,956
4 44,130 5,067 49,197
Total 167,244 16,505 183,749
Total 167,408 16,548 183,956
Pearson chi2(3) = 122.5582 Pr = 0.000
Pearson chi2(4) = 780.9703 Pr = 0.000
I4200 Active Diagnoses:
G0110G ADL Assistance: Alzheimers no yes Total
Dressing no yes Total no 134,410 13,850 148,260
0 8,971 439 9,410 yes 33,053 2,703 35,756
1 10,172 527 10,699
2 22,558 1,797 24,355 Total 167,463 16,553 184,016
3 96,382 10,772 107,154
4 29,356 3,013 32,369 Pearson chi2(1) = 111.7661 Pr = 0.000
Total 167,439 16,548 183,987 I4800 Active Diagnoses:
Dementia no yes Total
Pearson chi2(4) = 660.1047 Pr = 0.000 no 80,797 8,313 89,110
yes 86,642 8,244 94,886
G0110H ADL Assistance:
Eating no yes Total Total 167,439 16,557 183,996
0 44,848 3,926 48,774
1 61,226 5,974 67,200 Pearson chi2(1) =  23.0288 Pr = 0.000
2 18,186 1,997 20,183
3 25,343 2,823 28,166
4 17,883 1,839 19,722
Total 167,486 16,559 184,045


















Alabama 1,680 135 1,815
Alaska 224 21 245
Arizona 985 78 1,063
Arkansas 2,304 174 2,478
California 11,856 850 12,706
Colorado 2,284 146 2,430
Connecticut 3,105 191 3,296
Delaware 896 100 996
District of Columbia 1,239 128 1,367
Florida 9,770 1,142 10,912
Georgia 6,500 663 7,163
Hawaii 129 14 143
Idaho 713 53 766
Ill inois 7,198 832 8,030
Indiana 5,527 504 6,031
Iowa 2,794 400 3,194
Kansas 3,059 315 3,374
Kentucky 4,379 504 4,883
Louisiana 3,297 317 3,614
Maine 740 83 823
Maryland 4,042 330 4,372
Massachusetts 6,573 619 7,192
Michigan 2,594 274 2,868
Minnesota 1,912 127 2,039
Mississippi 1,590 99 1,689
Missouri 3,277 276 3,553
Montana 402 31 433
Nebraska 1,701 132 1,833
New Hampshire 1,270 122 1,392
New Jersey 4,760 403 5,163
New Mexico 369 31 400
New York 15,514 1,305 16,819
North Carolina 3,312 332 3,644
North Dakota 1,208 109 1,317
Ohio 9,296 1,155 10,451
Oklahoma 2,069 272 2,341
Oregon 723 54 777
Pennsylvania 9,716 988 10,704
Rhode Island 582 56 638
South Carolina 2,119 244 2,363
South Dakota 820 48 868
Tennessee 3,734 478 4,212
Texas 12,708 1,710 14,418
Utah 613 20 633
Virginia 1,303 140 1,443
Washington 1,606 143 1,749
West Virginia 599 67 666
Wisconsin 3,912 320 4,232
Wyoming 494 24 518
Total 167,497 16,559 184,056













Two-sample t test with unequal variances Bed Count by Falls
Group      Obs        Mean    Std. Err.   Std. Dev. [95% Conf. Interval]
no  148,538    141.3739    .1981318    76.36122 140.9856    141.7623
yes   35,449    135.1347     .385881     72.6533 134.3784    135.8911
combined  183,987    140.1718    .1764845    75.70076 139.8259    140.5177
diff             6.239189    .4337745 5.388988     7.08939
diff = mean(no) - mean(yes) t =  14.3835
Ho: diff = 0                             Welch's degrees of freedom =  55679.9
Ha: diff < 0                 Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 1.0000         Pr(T > t) = 0.0000 Pr(T > t) = 0.0000
Two-sample t test with unequal variances Bed Count by Infection
Group      Obs        Mean    Std. Err.   Std. Dev. [95% Conf. Interval]
0  167,497    140.6504    .1856421    75.97662 140.2866    141.0143
1   16,559    135.1449    .5639945    72.57581 134.0394    136.2504
combined  184,056    140.1551    .1764336    75.69312 139.8093    140.5009
diff             5.505536    .5937615 4.341715    6.669356
diff = mean(0) - mean(1) t =   9.2723
Ho: diff = 0                             Welch's degrees of freedom =  20317.1
Ha: diff < 0                 Ha: diff != 0 Ha: diff > 0
Pr(T < t) = 1.0000         Pr(T > t) = 0.0000 Pr(T > t) = 0.0000  Pr(T < t) = 1.0000         Pr(|T| > |t|) = 0.0000          Pr(T > t) = 0.0000
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0
Ho: diff = 0                             Welch's degrees of freedom =  20317.1
    diff = mean(0) - mean(1)                                      t =   9.2723
                                                                              
    diff              5.505536    .5937615                4.341715    6.669356
                                                                              
combined   184,056    140.1551    .1764336    75.69312    139.8093    140.5009
                                                                              
       1    16,559    135.1449    .5639945    72.57581    134.0394    136.2504
       0   167,497    140.6504    .1856421    75.97662    140.2866    141.0143
                                                                              
   Group       Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval]
                                                                              
Two-sample t test with unequal variances
 Pr(T < t) = 1.0000         Pr(|T| > |t|) = 0.0000          Pr(T > t) = 0.0000
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0
Ho: diff = 0                             Welch's degrees of freedom =  55679.9
    diff = mean(no) - mean(yes)                                   t =  14.3835
                                                                              
    diff              6.239189    .4337745                5.388988     7.08939
                                                                              
combined   183,987    140.1718    .1764845    75.70076    139.8259    140.5177
                                                                              
     yes    35,449    135.1347     .385881     72.6533    134.3784    135.8911
      no   148,538    141.3739    .1981318    76.36122    140.9856    141.7623
                                                                              
   Group       Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval]
                                                                              







Antipsychotic Medication – 2011 and 2013 
  
Antianxiety Medication – 2011 and 2013 
 












































Number of obs =    183,484






Scale parameter:  1 Prob > chi2 0.0000
Odds Ratio Std.Err. z P>z     
antipsychotic_13_bin 
yes 1.243007 0.020922 12.920000 0.000000 1.202670 1.284696
                                
antianxiety_13_bin 
yes 1.439696 0.024286 21.600000 0.000000 1.392875 1.488091
                                
antidepressant_13_bin 
yes 1.316230 0.019901 18.170000 0.000000 1.277798 1.355819
                                
hypnotic_13_bin 
yes 1.101404 0.034916 3.050000 0.002000 1.035051 1.172009
bedcount 0.999861 0.000123 -1.130000 0.259000 0.999620 1.000102
                                
hrdc_cna 
Med 1.02 0.03 0.61 0.544 0.96 1.07
High 1.09 0.04 2.44 0.015 1.02 1.16
                                
hrdc_lpn 
Med 0.97 0.02 -1.06 0.287 0.93 1.02
High 0.89 0.03 -3.53 0.000 0.84 0.95
                                
hrdc_rn 
Med 1.01 0.03 0.46 0.643 0.96 1.07
High 0.94 0.03 -1.76 0.079 0.88 1.01
                                
age 
75-84 1.222790 0.028658 8.580000 0.000000 1.167892 1.280269
85-94 1.352030 0.031697 12.870000 0.000000 1.291312 1.415603
95&older 1.530089 0.048831 13.330000 0.000000 1.437314 1.628852
                                
gender 
female 0.750186 0.012775 -16.880000 0.000000 0.725561 0.775647
                                
race 
Black 0.825416 0.022842 -6.930000 0.000000 0.781839 0.871423
Hispanic 0.903519 0.035015 -2.620000 0.009000 0.837433 0.974820
Asian 0.897911 0.062020 -1.560000 0.119000 0.784222 1.028080
AmericanIndian/AlaskanNative 1.074251 0.144328 0.530000 0.594000 0.825553 1.397868
NativeHawaiian/PacificIslander 0.830963 0.222369 -0.690000 0.489000 0.491809 1.403999
MultiRace 0.974616 0.137254 -0.180000 0.855000 0.739537 1.284419
Unknown 0.924841 0.051614 -1.400000 0.162000 0.829015 1.031743
                                
ADL_bedmobility 
1 0.830425 0.031899 -4.840000 0.000000 0.770200 0.895358
2 0.813613 0.030595 -5.490000 0.000000 0.755805 0.875843
3 0.712300 0.028661 -8.430000 0.000000 0.658283 0.770750
4 0.629131 0.033262 -8.770000 0.000000 0.567203 0.697820
                                
[95% Confidence Interval]
GEE population-averaged model
Group variable:                 residentID
Link:                                logit
Family:                           binomial








1 1.171600 0.051066 3.630000 0.000000 1.075668 1.276087
2 1.448026 0.065629 8.170000 0.000000 1.324943 1.582543
3 1.464386 0.072167 7.740000 0.000000 1.329557 1.612888
4 0.851770 0.048527 -2.820000 0.005000 0.761776 0.952395
                                
ADL_locomotion 
1 1.125476 0.030181 4.410000 0.000000 1.067851 1.186212
2 1.171036 0.032744 5.650000 0.000000 1.108586 1.237003
3 1.086336 0.030203 2.980000 0.003000 1.028723 1.147175
4 0.730209 0.023702 -9.690000 0.000000 0.685200 0.778174
                                
ADL_dressing 
1 0.993423 0.051739 -0.130000 0.899000 0.897021 1.100185
2 1.074676 0.054050 1.430000 0.152000 0.973794 1.186009
3 1.038774 0.054874 0.720000 0.471000 0.936603 1.152091
4 0.998686 0.061223 -0.020000 0.983000 0.885619 1.126187
                                
ADL_eating 
1 0.984860 0.017926 -0.840000 0.402000 0.950346 1.020628
2 1.022833 0.025262 0.910000 0.361000 0.974501 1.073562
3 0.970096 0.024409 -1.210000 0.228000 0.923416 1.019135
4 0.760099 0.030473 -6.840000 0.000000 0.702659 0.822235
                                
ADL_toileting 
1 1.003699 0.047396 0.080000 0.938000 0.914974 1.101028
2 1.223607 0.056585 4.360000 0.000000 1.117580 1.339692
3 1.274473 0.061736 5.010000 0.000000 1.159039 1.401403
4 1.123433 0.062240 2.100000 0.036000 1.007835 1.252291
                                
ADL_personalhygiene 
1 1.011927 0.048474 0.250000 0.805000 0.921243 1.111536
2 1.062809 0.049721 1.300000 0.193000 0.969692 1.164868
3 1.114429 0.054178 2.230000 0.026000 1.013145 1.225840
4 1.253550 0.070365 4.030000 0.000000 1.122953 1.399337
                                
self_understood 
usually understood 1.204838 0.021000 10.690000 0.000000 1.164374 1.246709
sometimes understood 1.249230 0.028829 9.640000 0.000000 1.193985 1.307031
rarely/never understood 1.061214 0.036197 1.740000 0.082000 0.992589 1.134583
                                
alzheimers 
yes 1.169186 0.022209 8.230000 0.000000 1.126457 1.213535
                                
dementia 















Alabama 1.252564 0.103534 2.720000 0.006000 1.065226 1.472849
Alaska 1.007882 0.237959 0.030000 0.973000 0.634517 1.600946
Arizona 1.537869 0.154294 4.290000 0.000000 1.263335 1.872061
Arkansas 1.411744 0.098175 4.960000 0.000000 1.231862 1.617892
California 0.914801 0.041127 -1.980000 0.048000 0.837643 0.999067
Colorado 1.695782 0.115752 7.740000 0.000000 1.483434 1.938526
Connecticut 1.209678 0.078229 2.940000 0.003000 1.065672 1.373144
Delaware 1.652414 0.172040 4.820000 0.000000 1.347401 2.026473
District of Columbia 1.130346 0.127032 1.090000 0.276000 0.906881 1.408875
Florida 0.988386 0.044077 -0.260000 0.793000 0.905664 1.078664
Georgia 1.565507 0.076263 9.200000 0.000000 1.422949 1.722348
Hawaii 1.556681 0.390203 1.770000 0.077000 0.952434 2.544278
Idaho 1.423830 0.161171 3.120000 0.002000 1.140529 1.777502
Illinois 1.157685 0.055010 3.080000 0.002000 1.054735 1.270683
Indiana 1.210949 0.062716 3.700000 0.000000 1.094060 1.340326
Iowa 1.373306 0.088664 4.910000 0.000000 1.210074 1.558558
Kansas 1.491885 0.091811 6.500000 0.000000 1.322368 1.683133
Kentucky 1.319287 0.073743 4.960000 0.000000 1.182390 1.472035
Louisiana 1.479397 0.091861 6.310000 0.000000 1.309877 1.670855
Maine 1.368829 0.157813 2.720000 0.006000 1.091978 1.715870
Maryland 1.399052 0.081553 5.760000 0.000000 1.248005 1.568381
Massachusetts 0.963052 0.049407 -0.730000 0.463000 0.870926 1.064924
Michigan 1.406079 0.094484 5.070000 0.000000 1.232571 1.604012
Minnesota 1.771768 0.126139 8.030000 0.000000 1.541014 2.037076
Mississippi 0.797133 0.076399 -2.370000 0.018000 0.660617 0.961859
Missouri 1.854432 0.106116 10.790000 0.000000 1.657687 2.074526
Montana 1.572800 0.221012 3.220000 0.001000 1.194158 2.071501
Nebraska 1.821221 0.136437 8.000000 0.000000 1.572516 2.109261
New Hampshire 1.643805 0.145425 5.620000 0.000000 1.382120 1.955036
New Jersey 0.968867 0.056463 -0.540000 0.587000 0.864288 1.086100
New Mexico 1.382776 0.231140 1.940000 0.053000 0.996478 1.918826
North Carolina 1.236611 0.076542 3.430000 0.001000 1.095334 1.396111
North Dakota 1.536046 0.134772 4.890000 0.000000 1.293362 1.824267
Ohio 1.233971 0.056394 4.600000 0.000000 1.128246 1.349603
Oklahoma 1.538923 0.109417 6.060000 0.000000 1.338742 1.769037
Oregon 1.352540 0.153294 2.660000 0.008000 1.083120 1.688977
Pennsylvania 1.244237 0.053734 5.060000 0.000000 1.143255 1.354140
Rhode Island 1.340641 0.181660 2.160000 0.031000 1.027951 1.748448
South Carolina 1.375878 0.101402 4.330000 0.000000 1.190820 1.589694
South Dakota 1.845432 0.190089 5.950000 0.000000 1.508064 2.258272
Tennessee 1.143011 0.068050 2.250000 0.025000 1.017123 1.284481
Texas 1.136530 0.047882 3.040000 0.002000 1.046453 1.234361
Utah 1.677039 0.195818 4.430000 0.000000 1.333992 2.108302
Virginia 1.659940 0.140027 6.010000 0.000000 1.406979 1.958381
Washington 1.308690 0.106574 3.300000 0.001000 1.115627 1.535163
West Virginia 2.187188 0.243774 7.020000 0.000000 1.757986 2.721178
Wisconsin 1.386949 0.079713 5.690000 0.000000 1.239193 1.552323
Wyoming 2.235585 0.271893 6.610000 0.000000 1.761439 2.837363








Number of obs =    183,515






Scale parameter:  1 Prob > chi2 0.0000
Odds Ratio Std.Err. z P>z     
med_yn 
yes 1.556768 0.026064 26.440000 0.000000 1.506512 1.608700
bedcount 0.999854 0.000123 -1.190000 0.235000 0.999613 1.000095
                                
hrdc_cna
Med 1.02 0.03 0.61 0.544 0.96 1.07
High 1.09 0.04 2.56 0.011 1.02 1.17
hrdc_lpn
Med 0.98 0.02 -0.98 0.328 0.93 1.02
High 0.89 0.03 -3.48 0.001 0.84 0.95
hrdc_rn
Med 1.00 0.03 0.10 0.922 0.95 1.06
High 0.93 0.03 -2.27 0.023 0.87 0.99
                                
age 
75-84 1.189378 0.027748 7.430000 0.000000 1.136219 1.245025
85-94 1.292003 0.029987 11.040000 0.000000 1.234546 1.352135
95&older 1.444712 0.045744 11.620000 0.000000 1.357780 1.537210
                                
gender 
female 0.766421 0.013015 -15.670000 0.000000 0.741331 0.792360
                                
race 
Black 0.794742 0.021938 -8.320000 0.000000 0.752887 0.838924
Hispanic 0.889871 0.034487 -3.010000 0.003000 0.824781 0.960097
Asian 0.877688 0.060689 -1.890000 0.059000 0.766449 1.005072
AmericanIndian/AlaskanNative 1.055113 0.141568 0.400000 0.689000 0.811129 1.372485
NativeHawaiian/PacificIslander 0.819301 0.218917 -0.750000 0.456000 0.485292 1.383196
MultiRace 0.958059 0.134678 -0.300000 0.761000 0.727336 1.261970
Unknown 0.912757 0.050863 -1.640000 0.101000 0.818318 1.018094
                                
ADL_bedmobility 
1 0.826207 0.031672 -4.980000 0.000000 0.766405 0.890674
2 0.808712 0.030347 -5.660000 0.000000 0.751368 0.870433
3 0.705514 0.028332 -8.690000 0.000000 0.652114 0.763287
4 0.620230 0.032729 -9.050000 0.000000 0.559288 0.687812
                                
[95% Confidence Interval]
GEE population-averaged model
Group variable:                 residentID
Link:                                logit
Family:                           binomial








1 1.165721 0.050712 3.520000 0.000000 1.070447 1.269474
2 1.439237 0.065087 8.050000 0.000000 1.317160 1.572629
3 1.453242 0.071483 7.600000 0.000000 1.319680 1.600321
4 0.847029 0.048153 -2.920000 0.003000 0.757719 0.946866
                                
ADL_locomotion 
1 1.132019 0.030295 4.630000 0.000000 1.074173 1.192980
2 1.176071 0.032815 5.810000 0.000000 1.113482 1.242178
3 1.092767 0.030321 3.200000 0.001000 1.034926 1.153840
4 0.732729 0.023748 -9.590000 0.000000 0.687630 0.780784
                                
ADL_dressing 
1 0.987801 0.051314 -0.240000 0.813000 0.892178 1.093673
2 1.070424 0.053744 1.360000 0.175000 0.970104 1.181117
3 1.036589 0.054666 0.680000 0.496000 0.934797 1.149466
4 1.001111 0.061265 0.020000 0.986000 0.887955 1.128687
                                
ADL_eating 
1 0.986154 0.017913 -0.770000 0.443000 0.951664 1.021895
2 1.027805 0.025320 1.110000 0.266000 0.979357 1.078650
3 0.977205 0.024527 -0.920000 0.358000 0.930297 1.026478
4 0.763228 0.030546 -6.750000 0.000000 0.705647 0.825507
                                
ADL_toileting 
1 1.004046 0.047361 0.090000 0.932000 0.915382 1.101298
2 1.224738 0.056583 4.390000 0.000000 1.118711 1.340814
3 1.276631 0.061768 5.050000 0.000000 1.161131 1.403620
4 1.126209 0.062302 2.150000 0.032000 1.010486 1.255185
                                
ADL_personalhygiene 
1 1.013247 0.048416 0.280000 0.783000 0.922661 1.112725
2 1.064915 0.049697 1.350000 0.178000 0.971833 1.166912
3 1.113470 0.053985 2.220000 0.027000 1.012532 1.224469
4 1.256882 0.070354 4.080000 0.000000 1.126285 1.402622
                                
self_understood 
usually understood 1.211660 0.021054 11.050000 0.000000 1.171089 1.253635
sometimes understood 1.260792 0.028962 10.090000 0.000000 1.205286 1.318854
rarely/never understood 1.065130 0.036240 1.850000 0.064000 0.996417 1.138581
                                
alzheimers 
yes 1.180267 0.022324 8.760000 0.000000 1.137313 1.224843
                                
dementia 















Alabama 1.292882 0.106714 3.110000 0.002000 1.099768 1.519905
Alaska 0.992849 0.234816 -0.030000 0.976000 0.624552 1.578332
Arizona 1.556330 0.156175 4.410000 0.000000 1.278453 1.894604
Arkansas 1.454651 0.100940 5.400000 0.000000 1.269677 1.666574
California 0.924999 0.041544 -1.740000 0.083000 0.847055 1.010114
Colorado 1.691506 0.115546 7.690000 0.000000 1.479546 1.933832
Connecticut 1.219729 0.078877 3.070000 0.002000 1.074530 1.384549
Delaware 1.700317 0.177183 5.090000 0.000000 1.386213 2.085595
District of Columbia 1.132253 0.127557 1.100000 0.270000 0.907924 1.412009
Florida 1.024339 0.045585 0.540000 0.589000 0.938779 1.117696
Georgia 1.593124 0.077537 9.570000 0.000000 1.448178 1.752577
Hawaii 1.531183 0.385840 1.690000 0.091000 0.934403 2.509111
Idaho 1.425358 0.161373 3.130000 0.002000 1.141706 1.779482
Illinois 1.171896 0.055672 3.340000 0.001000 1.067706 1.286253
Indiana 1.226287 0.063514 3.940000 0.000000 1.107911 1.357311
Iowa 1.402982 0.090549 5.250000 0.000000 1.236275 1.592169
Kansas 1.514169 0.093171 6.740000 0.000000 1.342139 1.708250
Kentucky 1.372451 0.076596 5.670000 0.000000 1.230246 1.531094
Louisiana 1.496784 0.092916 6.500000 0.000000 1.325314 1.690439
Maine 1.382701 0.159606 2.810000 0.005000 1.102741 1.733735
Maryland 1.400979 0.081689 5.780000 0.000000 1.249681 1.570594
Massachusetts 0.972579 0.049891 -0.540000 0.588000 0.879550 1.075448
Michigan 1.429857 0.095984 5.330000 0.000000 1.253583 1.630918
Minnesota 1.745306 0.124430 7.810000 0.000000 1.517700 2.007046
Mississippi 0.827601 0.079241 -1.980000 0.048000 0.685994 0.998440
Missouri 1.873528 0.107117 10.980000 0.000000 1.674918 2.095690
Montana 1.567386 0.219935 3.200000 0.001000 1.190517 2.063556
Nebraska 1.859405 0.139202 8.290000 0.000000 1.605646 2.153268
New Hampshire 1.675793 0.148241 5.840000 0.000000 1.409038 1.993050
New Jersey 0.987294 0.057560 -0.220000 0.826000 0.880685 1.106808
New Mexico 1.397923 0.233301 2.010000 0.045000 1.007918 1.938837
North Carolina 1.275823 0.078852 3.940000 0.000000 1.130270 1.440121
North Dakota 1.580914 0.138640 5.220000 0.000000 1.331254 1.877394
Ohio 1.264447 0.057759 5.140000 0.000000 1.156161 1.382876
Oklahoma 1.549263 0.109849 6.170000 0.000000 1.348254 1.780241
Oregon 1.337940 0.151814 2.570000 0.010000 1.071155 1.671172
Pennsylvania 1.268172 0.054751 5.500000 0.000000 1.165276 1.380153
Rhode Island 1.300923 0.176675 1.940000 0.053000 0.996900 1.697662
South Carolina 1.411891 0.104013 4.680000 0.000000 1.222062 1.631206
South Dakota 1.863341 0.191980 6.040000 0.000000 1.522625 2.280299
Tennessee 1.192788 0.070891 2.970000 0.003000 1.061633 1.340147
Texas 1.160629 0.048839 3.540000 0.000000 1.068747 1.260410
Utah 1.757658 0.204625 4.840000 0.000000 1.399065 2.208161
Virginia 1.705540 0.143718 6.340000 0.000000 1.445890 2.011817
Washington 1.324443 0.107943 3.450000 0.001000 1.128911 1.553841
West Virginia 2.225952 0.247630 7.190000 0.000000 1.789874 2.768274
Wisconsin 1.419201 0.081485 6.100000 0.000000 1.268152 1.588242
Wyoming 2.163658 0.263509 6.340000 0.000000 1.704204 2.746979







Number of obs =    183,515






Scale parameter:  1 Prob > chi2 0.0000
Odds Ratio Std.Err. z P>z     
med_multi 
1 1.393847 0.024975 18.530000 0.000000 1.345746 1.443668
2 1.792092 0.036666 28.510000 0.000000 1.721650 1.865416
3 2.243342 0.065248 27.780000 0.000000 2.119036 2.374940
4 2.477615 0.220465 10.200000 0.000000 2.081093 2.949688
bedcount 0.999854 0.000123 -1.190000 0.235000 0.999613 1.000095
                                
hrdc_cna
Med 1.02 0.03 0.61 0.542 0.96 1.07
High 1.09 0.04 2.46 0.014 1.02 1.16
hrdc_lpn
Med 0.98 0.02 -1.01 0.315 0.93 1.02
High 0.89 0.03 -3.51 0.000 0.84 0.95
hrdc_rn
Med 1.01 0.03 0.38 0.701 0.96 1.06
High 0.94 0.03 -1.80 0.072 0.88 1.01
age 
75-84 1.226394 0.028702 8.720000 0.000000 1.171410 1.283959
85-94 1.359659 0.031777 13.150000 0.000000 1.298782 1.423390
95&older 1.544123 0.049189 13.640000 0.000000 1.450662 1.643604
                                
gender 
female 0.754591 0.012830 -16.560000 0.000000 0.729860 0.780160
                                
race 
Black 0.821574 0.022707 -7.110000 0.000000 0.778254 0.867305
Hispanic 0.899310 0.034847 -2.740000 0.006000 0.833540 0.970270
Asian 0.896019 0.061947 -1.590000 0.112000 0.782472 1.026042
AmericanIndian/AlaskanNative 1.067323 0.143406 0.480000 0.628000 0.820217 1.388876
NativeHawaiian/PacificIslander 0.815310 0.218594 -0.760000 0.446000 0.482065 1.378923
MultiRace 0.971870 0.136878 -0.200000 0.839000 0.737437 1.280828
Unknown 0.922350 0.051462 -1.450000 0.147000 0.826806 1.028934
                                
ADL_bedmobility 
1 0.829269 0.031845 -4.880000 0.000000 0.769144 0.894093
2 0.813822 0.030594 -5.480000 0.000000 0.756016 0.876048
3 0.712572 0.028662 -8.420000 0.000000 0.658553 0.771023
4 0.628773 0.033231 -8.780000 0.000000 0.566902 0.697397
                                
[95% Confidence Interval]
GEE population-averaged model
Group variable:                 residentID
Link:                                logit
Family:                           binomial








1 1.169883 0.050967 3.600000 0.000000 1.074135 1.274165
2 1.447453 0.065568 8.160000 0.000000 1.324481 1.581841
3 1.464055 0.072121 7.740000 0.000000 1.329311 1.612458
4 0.853558 0.048600 -2.780000 0.005000 0.763427 0.954331
                                
ADL_locomotion 
1 1.124873 0.030155 4.390000 0.000000 1.067296 1.185555
2 1.171329 0.032744 5.660000 0.000000 1.108879 1.237296
3 1.087535 0.030228 3.020000 0.003000 1.029873 1.148424
4 0.731194 0.023728 -9.650000 0.000000 0.686137 0.779210
                                
ADL_dressing 
1 0.992121 0.051642 -0.150000 0.879000 0.895896 1.098680
2 1.073949 0.053994 1.420000 0.156000 0.973169 1.185165
3 1.039017 0.054871 0.720000 0.469000 0.936851 1.152324
4 1.000944 0.061341 0.020000 0.988000 0.887657 1.128688
                                
ADL_eating 
1 0.983094 0.017886 -0.940000 0.349000 0.948656 1.018783
2 1.022217 0.025232 0.890000 0.373000 0.973941 1.072886
3 0.970299 0.024393 -1.200000 0.230000 0.923649 1.019306
4 0.762349 0.030545 -6.770000 0.000000 0.704772 0.824629
                                
ADL_toileting 
1 1.004647 0.047430 0.100000 0.922000 0.915858 1.102044
2 1.224117 0.056606 4.370000 0.000000 1.118049 1.340246
3 1.273872 0.061700 5.000000 0.000000 1.158505 1.400727
4 1.123084 0.062207 2.100000 0.036000 1.007545 1.251873
                                
ADL_personalhygiene 
1 1.011385 0.048420 0.240000 0.813000 0.920800 1.110882
2 1.061423 0.049622 1.280000 0.202000 0.968488 1.163276
3 1.112188 0.054023 2.190000 0.029000 1.011189 1.223275
4 1.250824 0.070146 3.990000 0.000000 1.120627 1.396148
                                
self_understood 
usually understood 1.205309 0.020968 10.730000 0.000000 1.164905 1.247114
sometimes understood 1.251426 0.028792 9.750000 0.000000 1.196248 1.309150
rarely/never understood 1.067675 0.036353 1.920000 0.054000 0.998750 1.141357
                                
alzheimers 
yes 1.166861 0.022105 8.150000 0.000000 1.124332 1.211000
                                
dementia 















Alabama 1.262924 0.104270 2.830000 0.005000 1.074237 1.484754
Alaska 1.004295 0.237194 0.020000 0.986000 0.632157 1.595502
Arizona 1.537577 0.154284 4.290000 0.000000 1.263064 1.871751
Arkansas 1.419976 0.098653 5.050000 0.000000 1.239206 1.627116
California 0.912048 0.040965 -2.050000 0.040000 0.835191 0.995978
Colorado 1.699219 0.116039 7.760000 0.000000 1.486349 1.942574
Connecticut 1.206454 0.078021 2.900000 0.004000 1.062830 1.369486
Delaware 1.666224 0.173464 4.900000 0.000000 1.358684 2.043377
District of Columbia 1.134071 0.127544 1.120000 0.263000 0.909724 1.413745
Florida 0.992828 0.044235 -0.160000 0.872000 0.909806 1.083425
Georgia 1.567276 0.076312 9.230000 0.000000 1.424623 1.724213
Hawaii 1.551613 0.389606 1.750000 0.080000 0.948525 2.538153
Idaho 1.423666 0.161144 3.120000 0.002000 1.140409 1.777278
Illinois 1.158727 0.055038 3.100000 0.002000 1.055724 1.271781
Indiana 1.214103 0.062878 3.750000 0.000000 1.096914 1.343813
Iowa 1.382098 0.089215 5.010000 0.000000 1.217849 1.568499
Kansas 1.494499 0.091951 6.530000 0.000000 1.324720 1.686038
Kentucky 1.335311 0.074565 5.180000 0.000000 1.196880 1.489754
Louisiana 1.471514 0.091356 6.220000 0.000000 1.302925 1.661917
Maine 1.371535 0.158132 2.740000 0.006000 1.094126 1.719280
Maryland 1.401719 0.081695 5.790000 0.000000 1.250407 1.571342
Massachusetts 0.965963 0.049528 -0.680000 0.499000 0.873607 1.068082
Michigan 1.424120 0.095627 5.270000 0.000000 1.248504 1.624439
Minnesota 1.775505 0.126480 8.060000 0.000000 1.544137 2.041540
Mississippi 0.799271 0.076555 -2.340000 0.019000 0.662469 0.964323
Missouri 1.859208 0.106382 10.840000 0.000000 1.661970 2.079854
Montana 1.569561 0.220424 3.210000 0.001000 1.191896 2.066894
Nebraska 1.831885 0.137214 8.080000 0.000000 1.581760 2.121563
New Hampshire 1.651460 0.146114 5.670000 0.000000 1.388536 1.964169
New Jersey 0.973075 0.056710 -0.470000 0.640000 0.868038 1.090821
New Mexico 1.369869 0.228774 1.880000 0.060000 0.987472 1.900349
North Carolina 1.250071 0.077301 3.610000 0.000000 1.107385 1.411142
North Dakota 1.547258 0.135729 4.980000 0.000000 1.302847 1.837519
Ohio 1.245311 0.056893 4.800000 0.000000 1.138649 1.361964
Oklahoma 1.541957 0.109345 6.110000 0.000000 1.341871 1.771876
Oregon 1.353113 0.153359 2.670000 0.008000 1.083579 1.689691
Pennsylvania 1.251030 0.054016 5.190000 0.000000 1.149516 1.361508
Rhode Island 1.324189 0.179458 2.070000 0.038000 1.015296 1.727060
South Carolina 1.385181 0.102072 4.420000 0.000000 1.198899 1.600407
South Dakota 1.850837 0.190665 5.980000 0.000000 1.512450 2.264932
Tennessee 1.153278 0.068611 2.400000 0.017000 1.026347 1.295907
Texas 1.131905 0.047674 2.940000 0.003000 1.042219 1.229309
Utah 1.689129 0.197068 4.490000 0.000000 1.343861 2.123105
Virginia 1.662476 0.140202 6.030000 0.000000 1.409194 1.961282
Washington 1.317013 0.107275 3.380000 0.001000 1.122683 1.544981
West Virginia 2.227110 0.247976 7.190000 0.000000 1.790462 2.770246
Wisconsin 1.402129 0.080541 5.880000 0.000000 1.252833 1.569217
Wyoming 2.218251 0.269969 6.550000 0.000000 1.747497 2.815821








Number of obs =    183,516






Scale parameter:  1 Prob > chi2 0.0000
Odds Ratio Std.Err. z P>z     
antipsychotic_13_bin 
yes 0.955355 0.022826 -1.910000 0.056000 0.911649 1.001157
                                
antianxiety_13_bin 
yes 1.073440 0.025180 3.020000 0.003000 1.025205 1.123945
                                
antidepressant_13_bin 
yes 1.082333 0.021772 3.930000 0.000000 1.040492 1.125858
                                
hypnotic_13_bin 
yes 1.220417 0.049417 4.920000 0.000000 1.127305 1.321219
bedcount 0.999329 0.000168 -3.990000 0.000000 0.999000 0.999659
hrdc_cna
Med 0.96 0.03 -1.02 0.310 0.90 1.03
High 1.04 0.05 0.94 0.346 0.96 1.14
hrdc_lpn
Med 1.17 0.04 4.52 0.000 1.09 1.25
High 1.18 0.05 3.70 0.000 1.08 1.28
hrdc_rn
Med 0.86 0.03 -4.32 0.000 0.81 0.92
High 0.89 0.04 -2.74 0.006 0.82 0.97
                                
age 
75-84 1.012127 0.030278 0.400000 0.687000 0.954489 1.073245
85-94 0.986772 0.029632 -0.440000 0.657000 0.930370 1.046593
95&older 0.812842 0.035735 -4.710000 0.000000 0.745735 0.885987
                                
gender 
female 0.979986 0.022794 -0.870000 0.385000 0.936313 1.025695
                                
race 
Black 0.760753 0.027550 -7.550000 0.000000 0.708628 0.816713
Hispanic 0.848619 0.042419 -3.280000 0.001000 0.769422 0.935968
Asian 0.890351 0.084596 -1.220000 0.222000 0.739070 1.072598
AmericanIndian/AlaskanNative 1.347446 0.230523 1.740000 0.081000 0.963577 1.884240
NativeHawaiian/PacificIslander 1.200973 0.357457 0.620000 0.538000 0.670165 2.152210
MultiRace 1.063485 0.193094 0.340000 0.735000 0.745042 1.518035
Unknown 0.883749 0.066450 -1.640000 0.100000 0.762652 1.024075
                                
ADL_bedmobility 
1 0.887030 0.057379 -1.850000 0.064000 0.781406 1.006930
2 0.988013 0.059774 -0.200000 0.842000 0.877537 1.112397
3 1.079341 0.068014 1.210000 0.226000 0.953940 1.221228
4 1.090256 0.079463 1.190000 0.236000 0.945124 1.257673
                                
[95% Confidence Interval]
GEE population-averaged model
Group variable:                 residentID
Link:                                logit
Family:                           binomial







1 1.000769 0.074578 0.010000 0.992000 0.864771 1.158154
2 1.270766 0.095719 3.180000 0.001000 1.096351 1.472927
3 1.305342 0.104390 3.330000 0.001000 1.115971 1.526849
4 1.365929 0.116951 3.640000 0.000000 1.154911 1.615503
                                
ADL_locomotion 
1 1.043005 0.043669 1.010000 0.315000 0.960834 1.132204
2 1.156540 0.048560 3.460000 0.001000 1.065176 1.255741
3 1.323396 0.053606 6.920000 0.000000 1.222392 1.432745
4 1.429484 0.062734 8.140000 0.000000 1.311668 1.557882
                                
ADL_dressing 
1 1.017021 0.089551 0.190000 0.848000 0.855815 1.208593
2 1.143084 0.095329 1.600000 0.109000 0.970714 1.346062
3 1.216337 0.105103 2.270000 0.023000 1.026839 1.440807
4 1.134157 0.106509 1.340000 0.180000 0.943488 1.363358
                                
ADL_eating 
1 1.022784 0.025968 0.890000 0.375000 0.973133 1.074969
2 1.068648 0.035692 1.990000 0.047000 1.000932 1.140944
3 1.168246 0.038374 4.730000 0.000000 1.095405 1.245930
4 1.224866 0.055185 4.500000 0.000000 1.121343 1.337945
                                
ADL_toileting 
1 1.241588 0.100902 2.660000 0.008000 1.058770 1.455973
2 1.382066 0.109364 4.090000 0.000000 1.183512 1.613930
3 1.518572 0.124199 5.110000 0.000000 1.293655 1.782594
4 1.507309 0.132466 4.670000 0.000000 1.268811 1.790638
                                
ADL_personalhygiene 
1 0.951582 0.072341 -0.650000 0.514000 0.819853 1.104477
2 0.936589 0.067911 -0.900000 0.366000 0.812512 1.079614
3 0.880502 0.065230 -1.720000 0.086000 0.761503 1.018098
4 0.822071 0.067163 -2.400000 0.016000 0.700432 0.964834
                                
self_understood 
usually understood 0.954957 0.022602 -1.950000 0.051000 0.911671 1.000299
sometimes understood 0.759897 0.024487 -8.520000 0.000000 0.713387 0.809438
rarely/never understood 0.630627 0.027643 -10.520000 0.000000 0.578709 0.687202
                                
alzheimers 
yes 0.797250 0.021973 -8.220000 0.000000 0.755326 0.841501
                                
dementia 
yes 0.905416 0.018221 -4.940000 0.000000 0.870398 0.941842















Alabama 0.943371 0.110259 -0.500000 0.618000 0.750232 1.186231
Alaska 0.738016 0.207590 -1.080000 0.280000 0.425246 1.280832
Arizona 0.828506 0.121551 -1.280000 0.200000 0.621462 1.104526
Arkansas 0.846616 0.087841 -1.600000 0.109000 0.690828 1.037535
California 0.784335 0.046176 -4.130000 0.000000 0.698858 0.880266
Colorado 0.794724 0.089565 -2.040000 0.041000 0.637215 0.991167
Connecticut 0.724077 0.072293 -3.230000 0.001000 0.595388 0.880582
Delaware 1.197463 0.165606 1.300000 0.193000 0.913152 1.570295
District of Columbia 1.490815 0.183309 3.250000 0.001000 1.171550 1.897085
Florida 1.276986 0.070775 4.410000 0.000000 1.145539 1.423516
Georgia 1.253950 0.081624 3.480000 0.001000 1.103755 1.424582
Hawaii 1.114320 0.389476 0.310000 0.757000 0.561693 2.210654
Idaho 0.782940 0.134102 -1.430000 0.153000 0.559672 1.095273
Illinois 1.377928 0.083411 5.300000 0.000000 1.223772 1.551503
Indiana 0.904081 0.063941 -1.430000 0.154000 0.787057 1.038504
Iowa 1.618771 0.131286 5.940000 0.000000 1.380864 1.897666
Kansas 1.252927 0.107194 2.640000 0.008000 1.059502 1.481665
Kentucky 1.177691 0.085359 2.260000 0.024000 1.021730 1.357459
Louisiana 1.039278 0.088329 0.450000 0.650000 0.879807 1.227654
Maine 0.988435 0.149467 -0.080000 0.939000 0.734908 1.329422
Maryland 0.931075 0.074621 -0.890000 0.373000 0.795728 1.089442
Massachusetts 1.050248 0.069267 0.740000 0.457000 0.922896 1.195174
Michigan 1.152940 0.100711 1.630000 0.103000 0.971524 1.368234
Minnesota 0.674041 0.080117 -3.320000 0.001000 0.533964 0.850866
Mississippi 0.731179 0.097320 -2.350000 0.019000 0.563286 0.949114
Missouri 1.114704 0.095866 1.260000 0.207000 0.941793 1.319361
Montana 1.032097 0.226244 0.140000 0.885000 0.671630 1.586026
Nebraska 0.834733 0.099879 -1.510000 0.131000 0.660234 1.055352
New Hampshire 1.087191 0.137880 0.660000 0.510000 0.847920 1.393981
New Jersey 0.992128 0.074719 -0.100000 0.916000 0.855976 1.149936
New Mexico 0.892761 0.224441 -0.450000 0.652000 0.545434 1.461263
North Carolina 1.057553 0.086161 0.690000 0.492000 0.901474 1.240656
North Dakota 0.995702 0.133784 -0.030000 0.974000 0.765176 1.295680
Ohio 1.288569 0.075309 4.340000 0.000000 1.149107 1.444958
Oklahoma 1.454740 0.132750 4.110000 0.000000 1.216495 1.739645
Oregon 0.709620 0.124072 -1.960000 0.050000 0.503731 0.999660
Pennsylvania 1.067745 0.061474 1.140000 0.255000 0.953807 1.195293
Rhode Island 1.342933 0.248947 1.590000 0.112000 0.933819 1.931284
South Carolina 1.358920 0.126629 3.290000 0.001000 1.132078 1.631217
South Dakota 0.727518 0.137820 -1.680000 0.093000 0.501872 1.054617
Tennessee 1.315443 0.095834 3.760000 0.000000 1.140407 1.517345
Texas 1.486549 0.079035 7.460000 0.000000 1.339441 1.649814
Utah 0.346725 0.090792 -4.050000 0.000000 0.207537 0.579264
Virginia 1.168633 0.133666 1.360000 0.173000 0.933941 1.462302
Washington 0.866552 0.102388 -1.210000 0.225000 0.687418 1.092368
West Virginia 1.167730 0.189704 0.950000 0.340000 0.849298 1.605553
Wisconsin 0.950949 0.079800 -0.600000 0.549000 0.806729 1.120952
Wyoming 0.729116 0.175441 -1.310000 0.189000 0.454967 1.168460








Number of obs =    183,552






Scale parameter:  1 Prob > chi2 0.0000
Odds Ratio Std.Err. z P>z     
med_yn 
yes 1.115422 0.024108 5.050000 0.000000 1.069157 1.163688
bedcount 0.999322 0.000168 -4.030000 0.000000 0.998993 0.999651
hrdc_cna
Med 0.97 0.03 -0.93 0.352 0.90 1.04
High 1.05 0.05 1.05 0.294 0.96 1.14
hrdc_lpn
Med 1.17 0.04 4.62 0.000 1.09 1.25
High 1.18 0.05 3.82 0.000 1.08 1.29
hrdc_rn
Med 0.86 0.03 -4.30 0.000 0.81 0.92
High 0.89 0.04 -2.69 0.007 0.82 0.97
                                
age 
75-84 1.013788 0.030235 0.460000 0.646000 0.956227 1.074814
85-94 0.990203 0.029522 -0.330000 0.741000 0.934000 1.049788
95&older 0.815840 0.035676 -4.650000 0.000000 0.748829 0.888847
                                
gender 
female 0.984754 0.022860 -0.660000 0.508000 0.940953 1.030594
                                
race 
Black 0.753622 0.027225 -7.830000 0.000000 0.702106 0.808917
Hispanic 0.845584 0.042255 -3.360000 0.001000 0.766692 0.932593
Asian 0.892814 0.084825 -1.190000 0.233000 0.741122 1.075555
AmericanIndian/AlaskanNative 1.341327 0.229361 1.720000 0.086000 0.959364 1.875366
NativeHawaiian/PacificIslander 1.211140 0.359358 0.650000 0.519000 0.677071 2.166479
MultiRace 1.061171 0.192809 0.330000 0.744000 0.743236 1.515110
Unknown 0.884682 0.066347 -1.630000 0.102000 0.763749 1.024763
                                
ADL_bedmobility 
1 0.888300 0.057452 -1.830000 0.067000 0.782541 1.008352
2 0.991291 0.059943 -0.140000 0.885000 0.880499 1.116022
3 1.084808 0.068326 1.290000 0.196000 0.958827 1.227342
4 1.095149 0.079781 1.250000 0.212000 0.949433 1.263230
                                
[95% Confidence Interval]
GEE population-averaged model
Group variable:                 residentID
Link:                                logit
Family:                           binomial








1 1.004411 0.074833 0.060000 0.953000 0.867947 1.162332
2 1.277811 0.096215 3.260000 0.001000 1.102489 1.481014
3 1.312668 0.104940 3.400000 0.001000 1.122294 1.535334
4 1.375809 0.117745 3.730000 0.000000 1.163350 1.627068
                                
ADL_locomotion 
1 1.043165 0.043676 1.010000 0.313000 0.960979 1.132380
2 1.157002 0.048580 3.470000 0.001000 1.065599 1.256244
3 1.325770 0.053704 6.960000 0.000000 1.224583 1.435319
4 1.435035 0.062973 8.230000 0.000000 1.316769 1.563923
                                
ADL_dressing 
1 1.013928 0.089225 0.160000 0.875000 0.853300 1.204793
2 1.142128 0.095218 1.590000 0.111000 0.969954 1.344864
3 1.214101 0.104890 2.250000 0.025000 1.024984 1.438111
4 1.133945 0.106464 1.340000 0.181000 0.943353 1.363044
                                
ADL_eating 
1 1.018744 0.025849 0.730000 0.464000 0.969320 1.070688
2 1.063555 0.035496 1.850000 0.065000 0.996212 1.135451
3 1.163216 0.038160 4.610000 0.000000 1.090778 1.240465
4 1.222170 0.054993 4.460000 0.000000 1.119001 1.334850
                                
ADL_toileting 
1 1.243076 0.101088 2.680000 0.007000 1.059931 1.457867
2 1.382244 0.109412 4.090000 0.000000 1.183607 1.614217
3 1.516808 0.124108 5.090000 0.000000 1.292063 1.780646
4 1.503606 0.132176 4.640000 0.000000 1.265634 1.786323
ADL_personalhygiene 
1 0.947796 0.072013 -0.710000 0.480000 0.816661 1.099989
2 0.930978 0.067472 -0.990000 0.324000 0.807698 1.073074
3 0.871622 0.064532 -1.860000 0.063000 0.753891 1.007739
4 0.811877 0.066273 -2.550000 0.011000 0.691843 0.952738
                                
self_understood 
usually understood 0.948653 0.022409 -2.230000 0.026000 0.905733 0.993606
sometimes understood 0.753715 0.024218 -8.800000 0.000000 0.707712 0.802708
rarely/never understood 0.628556 0.027484 -10.620000 0.000000 0.576933 0.684799
                                
alzheimers 
yes 0.789611 0.021706 -8.590000 0.000000 0.748194 0.833320
                                
dementia 
yes 0.896091 0.017898 -5.490000 0.000000 0.861690 0.931866















Alabama 0.954703 0.111537 -0.400000 0.692000 0.759316 1.200366
Alaska 0.750584 0.211062 -1.020000 0.308000 0.432557 1.302431
Arizona 0.827028 0.121337 -1.290000 0.196000 0.620350 1.102564
Arkansas 0.847330 0.087918 -1.600000 0.110000 0.691406 1.038417
California 0.791656 0.046552 -3.970000 0.000000 0.705478 0.888361
Colorado 0.796212 0.089749 -2.020000 0.043000 0.638382 0.993062
Connecticut 0.725455 0.072394 -3.220000 0.001000 0.596580 0.882171
Delaware 1.212882 0.167641 1.400000 0.163000 0.925056 1.590264
District of Columbia 1.505030 0.185069 3.320000 0.001000 1.182702 1.915203
Florida 1.296398 0.071714 4.690000 0.000000 1.163192 1.444858
Georgia 1.270010 0.082625 3.670000 0.000000 1.117967 1.442731
Hawaii 1.136937 0.396653 0.370000 0.713000 0.573814 2.252694
Idaho 0.785906 0.134683 -1.410000 0.160000 0.561691 1.099622
Illinois 1.377192 0.083300 5.290000 0.000000 1.223233 1.550529
Indiana 0.906702 0.064105 -1.390000 0.166000 0.789376 1.041467
Iowa 1.623822 0.131676 5.980000 0.000000 1.385205 1.903542
Kansas 1.257956 0.107614 2.680000 0.007000 1.063770 1.487590
Kentucky 1.187924 0.086023 2.380000 0.017000 1.030740 1.369078
Louisiana 1.038192 0.088253 0.440000 0.659000 0.878861 1.226409
Maine 0.984256 0.148869 -0.100000 0.916000 0.731752 1.323891
Maryland 0.935221 0.074944 -0.840000 0.403000 0.799287 1.094272
Massachusetts 1.047269 0.069044 0.700000 0.484000 0.920323 1.191724
Michigan 1.154046 0.100785 1.640000 0.101000 0.972492 1.369495
Minnesota 0.673302 0.080032 -3.330000 0.001000 0.533374 0.849939
Mississippi 0.737935 0.098266 -2.280000 0.022000 0.568419 0.958004
Missouri 1.119127 0.096235 1.310000 0.191000 0.945548 1.324572
Montana 1.037663 0.227539 0.170000 0.866000 0.675157 1.594807
Nebraska 0.836913 0.100148 -1.490000 0.137000 0.661946 1.058129
New Hampshire 1.087082 0.137944 0.660000 0.511000 0.847715 1.394039
New Jersey 0.995478 0.074980 -0.060000 0.952000 0.858853 1.153838
New Mexico 0.942012 0.231140 -0.240000 0.808000 0.582370 1.523752
North Carolina 1.073152 0.087371 0.870000 0.386000 0.914872 1.258815
North Dakota 1.005298 0.135085 0.040000 0.969000 0.772531 1.308198
Ohio 1.295125 0.075648 4.430000 0.000000 1.155030 1.452212
Oklahoma 1.497042 0.135568 4.460000 0.000000 1.253579 1.787790
Oregon 0.710660 0.124197 -1.950000 0.051000 0.504548 1.000969
Pennsylvania 1.071980 0.061684 1.210000 0.227000 0.957650 1.199958
Rhode Island 1.340921 0.248676 1.580000 0.114000 0.932280 1.928677
South Carolina 1.373971 0.127966 3.410000 0.001000 1.144723 1.649130
South Dakota 0.729432 0.138186 -1.670000 0.096000 0.503187 1.057400
Tennessee 1.334576 0.097101 3.970000 0.000000 1.157208 1.539129
Texas 1.502953 0.079800 7.670000 0.000000 1.354410 1.667787
Utah 0.350117 0.091665 -4.010000 0.000000 0.209583 0.584883
Virginia 1.184124 0.135407 1.480000 0.139000 0.946368 1.481610
Washington 0.866897 0.102436 -1.210000 0.227000 0.687679 1.092821
West Virginia 1.173319 0.190666 0.980000 0.325000 0.853286 1.613383
Wisconsin 0.957732 0.080344 -0.510000 0.607000 0.812524 1.128889
Wyoming 0.726868 0.174918 -1.330000 0.185000 0.453542 1.164913







Number of obs =    183,552






Scale parameter:  1 Prob > chi2 0.0000
Odds Ratio Std.Err. z P>z     
med_multi 
1 1.107019 0.025514 4.410000 0.000000 1.058124 1.158173
2 1.115010 0.030569 3.970000 0.000000 1.056677 1.176563
3 1.184503 0.048225 4.160000 0.000000 1.093656 1.282897
4 1.250624 0.155889 1.790000 0.073000 0.979548 1.596716
                                
bedcount 0.999323 0.000168 -4.030000 0.000000 0.998993 0.999652
hrdc_cna 
Med 0.97 0.03 -0.93 0.353 0.90 1.04
High 1.05 0.05 1.04 0.298 0.96 1.14
                                
hrdc_lpn 
Med 1.17 0.04 4.61 0.000 1.09 1.25
High 1.18 0.05 3.82 0.000 1.08 1.29
                                
hrdc_rn 
Med 0.86 0.03 -4.28 0.000 0.81 0.92
High 0.89 0.04 -2.65 0.008 0.82 0.97
                                
age 
75-84 1.016900 0.030386 0.560000 0.575000 0.959055 1.078234
85-94 0.994941 0.029814 -0.170000 0.866000 0.938190 1.055124
95&older 0.820904 0.036050 -4.490000 0.000000 0.753203 0.894691
                                
gender 
female 0.983179 0.022845 -0.730000 0.465000 0.939409 1.028989
                                
race 
Black 0.755944 0.027356 -7.730000 0.000000 0.704184 0.811508
Hispanic 0.846218 0.042292 -3.340000 0.001000 0.767258 0.933303
Asian 0.894744 0.085021 -1.170000 0.242000 0.742704 1.077909
AmericanIndian/AlaskanNative 1.342035 0.229529 1.720000 0.085000 0.959803 1.876487
NativeHawaiian/PacificIslander 1.209628 0.359230 0.640000 0.522000 0.675874 2.164900
MultiRace 1.062701 0.193070 0.330000 0.738000 0.744331 1.517246
Unknown 0.885626 0.066424 -1.620000 0.105000 0.764554 1.025870
                                
ADL_bedmobility 
1 0.888814 0.057482 -1.820000 0.068000 0.782999 1.008929
2 0.992100 0.059993 -0.130000 0.896000 0.881217 1.116935
3 1.085989 0.068405 1.310000 0.190000 0.959863 1.228687
4 1.096612 0.079892 1.270000 0.206000 0.950693 1.264928
                                
[95% Confidence Interval]
GEE population-averaged model
Group variable:                 residentID
Link:                                logit
Family:                           binomial








1 1.004368 0.074822 0.060000 0.953000 0.867923 1.162263
2 1.277858 0.096217 3.260000 0.001000 1.102530 1.481066
3 1.313015 0.104964 3.410000 0.001000 1.122596 1.535733
4 1.376589 0.117811 3.730000 0.000000 1.164010 1.627990
                                
ADL_locomotion 
1 1.042435 0.043649 0.990000 0.321000 0.960301 1.131594
2 1.156396 0.048560 3.460000 0.001000 1.065032 1.255599
3 1.325163 0.053685 6.950000 0.000000 1.224011 1.434675
4 1.434673 0.062961 8.220000 0.000000 1.316430 1.563538
                                
ADL_dressing 
1 1.015013 0.089321 0.170000 0.866000 0.854212 1.206084
2 1.142657 0.095262 1.600000 0.110000 0.970404 1.345486
3 1.214539 0.104926 2.250000 0.024000 1.025355 1.438628
4 1.134105 0.106476 1.340000 0.180000 0.943491 1.363230
                                
ADL_eating 
1 1.018612 0.025846 0.730000 0.467000 0.969193 1.070550
2 1.063253 0.035488 1.840000 0.066000 0.995924 1.135135
3 1.162398 0.038137 4.590000 0.000000 1.090004 1.239600
4 1.221894 0.054982 4.450000 0.000000 1.118746 1.334552
                                
ADL_toileting 
1 1.243135 0.101074 2.680000 0.007000 1.060012 1.457892
2 1.382017 0.109381 4.090000 0.000000 1.183435 1.613921
3 1.516757 0.124090 5.090000 0.000000 1.292043 1.780555
4 1.503316 0.132138 4.640000 0.000000 1.265410 1.785949
                                
ADL_personalhygiene 
1 0.947815 0.072020 -0.710000 0.481000 0.816667 1.100025
2 0.930963 0.067478 -0.990000 0.324000 0.807673 1.073073
3 0.871852 0.064557 -1.850000 0.064000 0.754075 1.008024
4 0.811831 0.066276 -2.550000 0.011000 0.691792 0.952698
                                
self_understood 
usually understood 0.948144 0.022400 -2.250000 0.024000 0.905242 0.993080
sometimes understood 0.753270 0.024206 -8.820000 0.000000 0.707291 0.802239
rarely/never understood 0.628880 0.027499 -10.610000 0.000000 0.577228 0.685154
                                
alzheimers 
yes 0.788791 0.021694 -8.630000 0.000000 0.747397 0.832477
                                
dementia 
yes 0.894776 0.017901 -5.560000 0.000000 0.860369 0.930558










Alabama 0.952837 0.111327 -0.410000 0.679000 0.757821 1.198038
Alaska 0.751205 0.211272 -1.020000 0.309000 0.432876 1.303627
Arizona 0.824973 0.121068 -1.310000 0.190000 0.618761 1.099908
Arkansas 0.845295 0.087720 -1.620000 0.105000 0.689725 1.035954
California 0.790176 0.046473 -4.000000 0.000000 0.704145 0.886719
Colorado 0.796245 0.089760 -2.020000 0.043000 0.638399 0.993120
Connecticut 0.724840 0.072346 -3.220000 0.001000 0.596052 0.881455
Delaware 1.210304 0.167313 1.380000 0.167000 0.923048 1.586956
District of Columbia 1.503285 0.184865 3.310000 0.001000 1.181315 1.913008
Florida 1.291855 0.071514 4.630000 0.000000 1.159026 1.439906
Georgia 1.267299 0.082468 3.640000 0.000000 1.115547 1.439695
Hawaii 1.134579 0.395911 0.360000 0.717000 0.572543 2.248335
Idaho 0.785306 0.134574 -1.410000 0.158000 0.561272 1.098766
Illinois 1.375064 0.083191 5.260000 0.000000 1.221310 1.548176
Indiana 0.905502 0.064027 -1.400000 0.160000 0.788319 1.040104
Iowa 1.619631 0.131371 5.940000 0.000000 1.381572 1.898710
Kansas 1.255109 0.107384 2.660000 0.008000 1.061340 1.484254
Kentucky 1.185077 0.085843 2.340000 0.019000 1.028226 1.365856
Louisiana 1.036453 0.088122 0.420000 0.674000 0.877361 1.224394
Maine 0.983525 0.148766 -0.110000 0.913000 0.731197 1.322929
Maryland 0.935010 0.074932 -0.840000 0.402000 0.799099 1.094036
Massachusetts 1.046745 0.069014 0.690000 0.488000 0.919855 1.191139
Michigan 1.154250 0.100805 1.640000 0.100000 0.972660 1.369742
Minnesota 0.674030 0.080129 -3.320000 0.001000 0.533935 0.850884
Mississippi 0.736038 0.098021 -2.300000 0.021000 0.566946 0.955561
Missouri 1.117717 0.096118 1.290000 0.196000 0.944349 1.322912
Montana 1.037114 0.227429 0.170000 0.868000 0.674787 1.593995
Nebraska 0.834498 0.099882 -1.510000 0.131000 0.660001 1.055130
New Hampshire 1.086533 0.137883 0.650000 0.513000 0.847274 1.393355
New Jersey 0.994101 0.074880 -0.080000 0.937000 0.857659 1.152249
New Mexico 0.939208 0.230486 -0.260000 0.798000 0.580594 1.519325
North Carolina 1.071183 0.087216 0.840000 0.398000 0.913185 1.256519
North Dakota 1.002852 0.134768 0.020000 0.983000 0.770635 1.305044
Ohio 1.292616 0.075519 4.390000 0.000000 1.152762 1.449437
Oklahoma 1.496466 0.135515 4.450000 0.000000 1.253097 1.787101
Oregon 0.710311 0.124161 -1.960000 0.050000 0.504267 1.000546
Pennsylvania 1.070566 0.061612 1.180000 0.236000 0.956371 1.198397
Rhode Island 1.342479 0.248950 1.590000 0.112000 0.933384 1.930877
South Carolina 1.371398 0.127743 3.390000 0.001000 1.142551 1.646082
South Dakota 0.728014 0.137958 -1.680000 0.094000 0.502155 1.055461
Tennessee 1.329299 0.096775 3.910000 0.000000 1.152536 1.533173
Texas 1.498457 0.079611 7.610000 0.000000 1.350272 1.662905
Utah 0.349099 0.091405 -4.020000 0.000000 0.208967 0.583203
Virginia 1.181665 0.135138 1.460000 0.144000 0.944384 1.478563
Washington 0.865734 0.102320 -1.220000 0.223000 0.686724 1.091408
West Virginia 1.174088 0.190788 0.990000 0.323000 0.853849 1.614434
Wisconsin 0.956398 0.080240 -0.530000 0.595000 0.811380 1.127334
Wyoming 0.728502 0.175310 -1.320000 0.188000 0.454562 1.167529
_cons 0.046319 0.004534 -31.390000 0.000000 0.038234 0.056114
